



US009713731B2

(12) **United States Patent**
Slayton et al.

(10) **Patent No.:** **US 9,713,731 B2**
(45) **Date of Patent:** ***Jul. 25, 2017**

- (54) **ENERGY BASED FAT REDUCTION**
- (71) Applicant: **Guided Therapy Systems, LLC**, Mesa, AZ (US)
- (72) Inventors: **Michael H. Slayton**, Tempe, AZ (US); **Peter G. Barthe**, Phoenix, AZ (US)
- (73) Assignee: **Guided Therapy Systems, LLC**, Mesa, AZ (US)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **15/380,267**

(22) Filed: **Dec. 15, 2016**

(65) **Prior Publication Data**
US 2017/0095680 A1 Apr. 6, 2017

Related U.S. Application Data
(63) Continuation of application No. 15/041,804, filed on Feb. 11, 2016, now Pat. No. 9,533,175, which is a (Continued)

(51) **Int. Cl.**
A61N 7/00 (2006.01)
A61B 5/00 (2006.01)
(Continued)

(52) **U.S. Cl.**
CPC *A61N 7/00* (2013.01); *A61B 5/4869* (2013.01); *A61B 8/0858* (2013.01);
(Continued)

(58) **Field of Classification Search**
CPC ... A61B 5/682; A61B 17/320068; A61B 8/08; A61B 8/0858; A61B 8/12; A61B 8/4483;
(Continued)

(56) **References Cited**
U.S. PATENT DOCUMENTS

2,427,348 A 9/1947 Bond et al.
2,792,829 A 2/1952 Calosi
(Continued)

FOREIGN PATENT DOCUMENTS

CN 104027893 9/2014
DE 4029175 3/1992
(Continued)

OTHER PUBLICATIONS

Agren, Magnus S. et al., Collagenase in Wound Healing: Effect of Wound Age and Type. The Journal of Investigative Dermatology, vol. 99/No. 6, (Dec. 1992).

(Continued)


Primary Examiner — Bo J Peng

(74) *Attorney, Agent, or Firm* — Knobbe, Martens, Olson & Bear, LLP

(57) **ABSTRACT**

Methods for non-invasive fat reduction can include targeting a region of interest below a surface of skin, which contains fat and delivering ultrasound energy to the region of interest. The ultrasound energy generates a thermal lesion with said ultrasound energy on a fat cell. The lesion can create an opening in the surface of the fat cell, which allows the draining of a fluid out of the fat cell and through the opening. In addition, by applying ultrasound energy to fat cells to increase the temperature to between 43 degrees and 49 degrees, cell apoptosis can be realized, thereby resulting in reduction of fat.

20 Claims, 27 Drawing Sheets



Related U.S. Application Data				
	continuation of application No. 14/550,772, filed on Nov. 21, 2014, now Pat. No. 9,283,409, which is a continuation of application No. 14/192,520, filed on Feb. 27, 2014, now Pat. No. 8,920,324, which is a continuation of application No. 12/646,609, filed on Dec. 23, 2009, now Pat. No. 8,663,112, which is a continuation-in-part of application No. 11/163,154, filed on Oct. 6, 2005, now Pat. No. 8,133,180.	4,567,895 A	2/1986	Putzke
		4,586,512 A	5/1986	Do-Huu
		4,601,296 A	7/1986	Yerushalmi
		4,620,546 A	11/1986	Aida et al.
		4,637,256 A	1/1987	Sugiyama et al.
		4,646,756 A	3/1987	Walmough
		4,663,358 A	5/1987	Hyon
		4,668,516 A	5/1987	Duraffourd et al.
		4,672,591 A	6/1987	Breimesser et al.
		4,680,499 A	7/1987	Umemura et al.
		4,697,588 A	10/1987	Reichenberger
		4,754,760 A	7/1988	Fukukita et al.
		4,757,820 A	7/1988	Itoh
		4,771,205 A	9/1988	Mequio
		4,801,459 A	1/1989	Liburdy
		4,803,625 A	2/1989	Fu et al.
		4,807,633 A	2/1989	Fry
		4,817,615 A	4/1989	Fukukita et al.
		4,858,613 A	8/1989	Fry
		4,860,732 A	8/1989	Hasegawa et al.
		4,865,041 A	9/1989	Hassler
		4,865,042 A	9/1989	Umemura
		4,867,169 A	9/1989	Machida
		4,874,562 A	10/1989	Hyon
		4,875,487 A	10/1989	Seppi
		4,881,212 A	11/1989	Takeuchi
		4,891,043 A	1/1990	Zeimer et al.
		4,893,624 A	1/1990	Lele
		4,896,673 A	1/1990	Rose
		4,900,540 A	2/1990	Ryan et al.
		4,901,729 A	2/1990	Saitoh
		4,917,096 A	4/1990	Englehart
		4,932,414 A	6/1990	Coleman et al.
		4,938,216 A	7/1990	Lele
		4,938,217 A	7/1990	Lele
		4,947,046 A	8/1990	Kawabata et al.
		4,951,653 A	8/1990	Fry
		4,955,365 A	9/1990	Fry
		4,958,626 A	9/1990	Nambu
		4,976,709 A	12/1990	Sand
		4,979,501 A	12/1990	Valchanov
		4,992,989 A	2/1991	Watanabe et al.
		5,012,797 A	5/1991	Liang
		5,018,508 A	5/1991	Fry et al.
		5,030,874 A	7/1991	Saito et al.
		5,036,855 A	8/1991	Fry
		5,040,537 A	8/1991	Katakura
		5,054,310 A	10/1991	Flynn
		5,054,470 A	10/1991	Fry
		5,054,491 A	10/1991	Saito et al.
		5,070,879 A	12/1991	Herres
		5,088,495 A	2/1992	Miyagawa
		5,115,814 A	5/1992	Griffith
		5,117,832 A	6/1992	Sanghvi
		5,123,418 A	6/1992	Saurel
		5,142,511 A	8/1992	Kanai et al.
		5,143,063 A	9/1992	Fellner
		5,143,074 A	9/1992	Dory
		5,149,319 A	9/1992	Unger
		5,150,711 A	9/1992	Dory
		5,150,714 A	9/1992	Green
		5,152,294 A	10/1992	Mochizuki et al.
		5,156,144 A	10/1992	Iwasaki
		5,158,536 A	10/1992	Sekins
		5,159,931 A	11/1992	Pini
		5,163,421 A	11/1992	Bernstein
		5,163,436 A	11/1992	Saitoh et al.
		5,178,135 A	1/1993	Uchiyama et al.
		5,190,518 A	3/1993	Takasu
		5,190,766 A	3/1993	Ishihara
		5,191,880 A	3/1993	McLeod
		5,205,287 A	4/1993	Erbel et al.
		5,209,720 A	5/1993	Unger
		5,212,671 A	5/1993	Fujii et al.
		5,215,680 A	6/1993	D'Arrigo
		5,224,467 A	7/1993	Oku
		5,230,334 A	7/1993	Klopotek
		5,230,338 A	7/1993	Allen et al.
		5,247,924 A	9/1993	Suzuki et al.
(60)	Provisional application No. 60/616,753, filed on Oct. 6, 2004, provisional application No. 61/140,725, filed on Dec. 24, 2008.			
(51)	Int. Cl. <i>A61B 8/08</i> (2006.01) <i>B06B 1/06</i> (2006.01) <i>G01S 15/89</i> (2006.01) <i>G01S 7/52</i> (2006.01) <i>A61N 7/02</i> (2006.01) <i>A61B 90/00</i> (2016.01)			
(52)	U.S. Cl. CPC <i>B06B 1/0607</i> (2013.01); <i>G01S 7/5208</i> (2013.01); <i>G01S 15/899</i> (2013.01); <i>A61B 2090/378</i> (2016.02); <i>A61N 2007/0008</i> (2013.01); <i>A61N 2007/0052</i> (2013.01); <i>A61N 2007/027</i> (2013.01)			
(58)	Field of Classification Search CPC A61B 8/483; A61B 8/546; A61B 8/13; A61B 8/461; A61B 5/6842; A61B 8/4209; A61B 8/4281; A61B 8/4455; A61H 23/0245; A61H 2201/50; A61N 7/00; A61N 7/02; G01S 15/8909 See application file for complete search history.			
(56)	References Cited U.S. PATENT DOCUMENTS			
	3,913,386 A	10/1975	Saglio	
	3,965,455 A	6/1976	Hurwitz	
	3,992,925 A	11/1976	Perilhou	
	4,039,312 A	8/1977	Patru	
	4,059,098 A	11/1977	Murdock	
	4,101,795 A	7/1978	Fukumoto	
	4,151,834 A	5/1979	Sato et al.	
	4,166,967 A	9/1979	Benes et al.	
	4,211,948 A	7/1980	Smith et al.	
	4,211,949 A	7/1980	Brisken et al.	
	4,213,344 A	7/1980	Rose	
	4,276,491 A	6/1981	Daniel	
	4,315,514 A	2/1982	Drewes et al.	
	4,325,381 A	4/1982	Glenn	
	4,343,301 A	8/1982	Indech	
	4,372,296 A	2/1983	Fahim	
	4,379,145 A	4/1983	Masuh et al.	
	4,381,007 A	4/1983	Doss	
	4,381,787 A	5/1983	Hottinger	
	4,397,314 A	8/1983	Vaguine	
	4,409,839 A	10/1983	Taenzer	
	4,431,008 A	2/1984	Wanner et al.	
	4,441,486 A	4/1984	Pounds	
	4,452,084 A	6/1984	Taenzer	
	4,484,569 A	11/1984	Driller	
	4,507,582 A	3/1985	Glenn	
	4,513,749 A	4/1985	Kino	
	4,513,750 A	4/1985	Heyman et al.	
	4,527,550 A	7/1985	Ruggera et al.	
	4,528,979 A	7/1985	Marchenko	
	4,534,221 A	8/1985	Fife et al.	
	4,566,459 A	1/1986	Umemura et al.	

(56)	References Cited	5,601,526 A *	2/1997	Chapelon	A61N 7/02 601/2
	U.S. PATENT DOCUMENTS	5,603,323 A	2/1997	Pflugrath et al.	
		5,605,154 A *	2/1997	Ries	G01S 7/52046 600/444
5,255,681 A	10/1993	Ishimura et al.			
5,257,970 A	11/1993	Dougherty		5,609,562 A	3/1997
5,265,614 A	11/1993	Hayakawa		5,615,091 A	3/1997
5,267,985 A	12/1993	Shimada		5,617,858 A	4/1997
5,269,297 A	12/1993	Weng		5,618,275 A	4/1997
5,282,797 A	2/1994	Chess		5,620,479 A	4/1997
5,295,484 A	3/1994	Marcus		5,622,175 A	4/1997
5,295,486 A	3/1994	Wollschlager et al.		5,638,819 A	6/1997
5,304,169 A	4/1994	Sand		5,643,179 A *	7/1997
5,305,756 A	4/1994	Entrekin et al.			A61N 7/02 601/2
5,321,520 A	6/1994	Inga et al.		5,644,085 A	7/1997
5,323,779 A	6/1994	Hardy et al.		5,647,373 A	7/1997
5,327,895 A	7/1994	Hashimoto et al.		5,655,535 A	8/1997
5,348,016 A	9/1994	Unger et al.		5,655,538 A	8/1997
5,358,466 A *	10/1994	Aida	A61B 17/2256 600/439	5,657,760 A	8/1997
				5,658,328 A	8/1997
5,360,268 A	11/1994	Hayashi		5,660,836 A *	8/1997
5,370,121 A	12/1994	Reichenberger			A61B 18/12 128/898
5,370,122 A	12/1994	Kunig et al.		5,662,116 A	9/1997
5,371,483 A	12/1994	Bhardwaj		5,665,053 A	9/1997
5,375,602 A	12/1994	Lancee et al.		5,665,141 A	9/1997
5,379,773 A	1/1995	Hornsby		5,671,746 A	9/1997
5,380,280 A	1/1995	Peterson		5,673,699 A	10/1997
5,380,519 A	1/1995	Schneider et al.		5,676,692 A	10/1997
5,383,917 A	1/1995	Desai et al.		5,685,820 A	11/1997
5,391,140 A	2/1995	Schaetzle et al.		5,690,608 A	11/1997
5,391,197 A	2/1995	Burdette et al.		5,694,936 A	12/1997
5,392,259 A	2/1995	Bolorforosh		5,697,897 A	12/1997
5,396,143 A	3/1995	Seyed-Bolorforosh et al.		5,701,900 A	12/1997
5,398,689 A	3/1995	Connor et al.		5,704,361 A	1/1998
5,406,503 A	4/1995	Williams		5,706,252 A	1/1998
5,413,550 A *	5/1995	Castel	A61H 23/0245 601/2	5,706,564 A	1/1998
				5,715,823 A	2/1998
5,417,216 A	5/1995	Tanaka		5,720,287 A	2/1998
5,419,327 A	5/1995	Rohwedder		5,722,411 A	3/1998
5,423,220 A	6/1995	Finsterwald et al.		5,727,554 A	3/1998
5,435,311 A	7/1995	Umemura		5,735,280 A	4/1998
5,438,998 A	8/1995	Hanafy		5,743,863 A	4/1998
5,443,068 A *	8/1995	Cline	A61B 5/0555 600/411	5,746,005 A	5/1998
				5,746,762 A	5/1998
5,445,611 A	8/1995	Eppstein et al.		5,748,767 A	5/1998
5,458,596 A	10/1995	Lax		5,749,364 A	5/1998
5,460,179 A	10/1995	Okunuki et al.		5,755,228 A	5/1998
5,460,595 A	10/1995	Hall et al.		5,755,753 A	5/1998
5,469,854 A	11/1995	Unger et al.		5,762,066 A	6/1998
5,471,988 A	12/1995	Fujio		5,763,886 A	6/1998
5,472,405 A	12/1995	Buchholtz et al.		5,769,790 A	6/1998
5,487,388 A	1/1996	Rello et al.		5,779,644 A	7/1998
5,492,126 A	2/1996	Hennige		5,792,058 A	8/1998
5,496,256 A	3/1996	Bock		5,795,297 A	8/1998
5,501,655 A	3/1996	Rolt		5,795,311 A	8/1998
5,503,152 A	4/1996	Oakley et al.		5,810,009 A	9/1998
5,503,320 A	4/1996	Webster et al.		5,810,888 A	9/1998
5,507,790 A	4/1996	Weiss		5,814,599 A	9/1998
5,511,296 A	4/1996	Dias et al.		5,817,013 A	10/1998
5,520,188 A	5/1996	Hennige		5,817,021 A	10/1998
5,522,869 A	6/1996	Burdette		5,820,564 A	10/1998
5,523,058 A	6/1996	Umemura et al.		5,823,962 A	10/1998
5,524,620 A	6/1996	Rosenschein		5,827,204 A	10/1998
5,524,624 A	6/1996	Tepper		5,840,032 A	11/1998
5,524,625 A	6/1996	Okazaki		5,844,140 A	12/1998
5,526,624 A	6/1996	Berg		5,853,367 A	12/1998
5,526,812 A	6/1996	Dumoulin et al.		5,869,751 A	2/1999
5,526,814 A	6/1996	Cline et al.		5,871,524 A	2/1999
5,526,815 A	6/1996	Granz		5,873,902 A	2/1999
5,529,070 A	6/1996	Augustine et al.		5,876,341 A	3/1999
5,540,235 A	7/1996	Wilson		5,879,303 A	3/1999
5,558,092 A	9/1996	Unger		5,882,557 A	3/1999
5,560,362 A	10/1996	Sliwa et al.		5,891,034 A	4/1999
5,575,291 A	11/1996	Hayakawa		5,895,356 A	4/1999
5,575,807 A	11/1996	Faller		5,899,861 A	5/1999
5,577,502 A	11/1996	Darrow et al.		5,904,659 A	5/1999
5,577,507 A	11/1996	Snyder et al.		5,919,219 A	7/1999
5,577,991 A	11/1996	Akui et al.		5,923,099 A	7/1999
5,580,575 A	12/1996	Unger et al.		5,924,989 A	7/1999

(56)

References Cited

U.S. PATENT DOCUMENTS

5,928,169 A	7/1999	Schatzle et al.	6,273,864 B1	8/2001	Duarte
5,931,805 A	8/1999	Brisken	6,280,402 B1	8/2001	Ishibashi et al.
5,938,606 A	8/1999	Bonnefous	6,287,257 B1	9/2001	Matichuk
5,938,612 A	8/1999	Kline-Schoder	6,287,304 B1	9/2001	Eggers et al.
5,948,011 A	9/1999	Knowlton	6,296,619 B1	10/2001	Brisken
5,957,844 A	9/1999	Dekel	6,301,989 B1	10/2001	Brown et al.
5,957,882 A	9/1999	Nita et al.	6,307,302 B1	10/2001	Toda
5,957,941 A	9/1999	Ream	6,309,355 B1	10/2001	Cain et al.
5,964,707 A	10/1999	Fenster et al.	6,311,090 B1	10/2001	Knowlton
5,967,980 A	10/1999	Ferre et al.	6,315,741 B1 *	11/2001	Martin A61B 8/4254 601/3
5,968,034 A	10/1999	Fullmer	6,322,509 B1	11/2001	Pan et al.
5,971,949 A	10/1999	Levin	6,322,532 B1	11/2001	D'Sa
5,977,538 A	11/1999	Unger et al.	6,325,540 B1	12/2001	Lounsberry et al.
5,984,881 A *	11/1999	Ishibashi A61B 17/2256 601/2	6,325,758 B1	12/2001	Carol et al.
5,984,882 A	11/1999	Rosenschein	6,325,769 B1	12/2001	Klopotek
5,990,598 A	11/1999	Sudol et al.	6,325,798 B1	12/2001	Edwards et al.
5,997,471 A	12/1999	Gumb et al.	6,338,716 B1	1/2002	Hossack et al.
5,997,497 A	12/1999	Nita et al.	6,350,276 B1	2/2002	Knowlton
5,999,843 A	12/1999	Anbar	6,356,780 B1	3/2002	Licato et al.
6,004,262 A	12/1999	Putz et al.	6,361,531 B1	3/2002	Hissong
6,007,499 A	12/1999	Martin et al.	6,370,411 B1	4/2002	Osadchy et al.
6,013,032 A	1/2000	Savord	6,375,672 B1	4/2002	Aksan
6,014,473 A	1/2000	Hossack et al.	6,377,854 B1	4/2002	Knowlton
6,016,255 A	1/2000	Bolan et al.	6,377,855 B1	4/2002	Knowlton
6,019,724 A	2/2000	Gronningsaeter et al.	6,381,497 B1	4/2002	Knowlton
6,022,308 A	2/2000	Williams	6,381,498 B1	4/2002	Knowlton
6,022,327 A	2/2000	Chang	6,387,380 B1	5/2002	Knowlton
6,030,374 A	2/2000	McDaniel	6,390,982 B1	5/2002	Bova et al.
6,036,646 A	3/2000	Barthe	6,405,090 B1	6/2002	Knowlton
6,039,048 A	3/2000	Silberg	6,409,720 B1	6/2002	Hissong
6,039,689 A	3/2000	Lizzi	6,413,216 B1	7/2002	Cain et al.
6,042,556 A *	3/2000	Beach A61N 7/02 600/437	6,413,253 B1	7/2002	Koop
6,049,159 A	4/2000	Barthe	6,413,254 B1	7/2002	Hissong
6,050,943 A	4/2000	Slayton	6,419,648 B1	7/2002	Vitek
6,059,727 A	5/2000	Fowlkes	6,423,007 B2	7/2002	Lizzi et al.
6,071,239 A	6/2000	Cribbs	6,425,865 B1	7/2002	Salcudean
6,080,108 A	6/2000	Dunham	6,425,867 B1	7/2002	Vaezy
6,083,148 A	7/2000	Williams	6,425,912 B1	7/2002	Knowlton
6,086,535 A	7/2000	Ishibashi	6,428,477 B1	8/2002	Mason
6,086,580 A	7/2000	Mordon et al.	6,428,532 B1	8/2002	Doukas
6,090,054 A	7/2000	Tagishi	6,430,446 B1	8/2002	Knowlton
6,093,148 A *	7/2000	Fujimoto A61N 7/00 600/438	6,432,057 B1	8/2002	Mazess et al.
6,093,883 A	7/2000	Sanghvi	6,432,067 B1	8/2002	Martin
6,101,407 A	8/2000	Groezinger	6,432,101 B1	8/2002	Weber
6,106,469 A	8/2000	Suzuki et al.	6,436,061 B1	8/2002	Costantino
6,113,558 A	9/2000	Rosenschein	6,438,424 B1	8/2002	Knowlton
6,113,559 A	9/2000	Klopotek	6,440,071 B1	8/2002	Slayton
6,120,452 A	9/2000	Barthe	6,440,121 B1	8/2002	Weber
6,123,081 A	9/2000	Durette	6,443,914 B1	9/2002	Costantino
6,126,619 A	10/2000	Peterson et al.	6,447,443 B1	9/2002	Keogh et al.
6,135,971 A	10/2000	Hutchinson	6,451,013 B1	9/2002	Bays et al.
6,139,499 A	10/2000	Wilk	6,453,202 B1	9/2002	Knowlton
6,159,150 A	12/2000	Yale et al.	6,461,304 B1	10/2002	Tanaka et al.
6,171,244 B1	1/2001	Finger et al.	6,461,378 B1	10/2002	Knowlton
6,176,840 B1	1/2001	Nishimura	6,470,216 B1	10/2002	Knowlton
6,183,426 B1	2/2001	Akisada	6,488,626 B1	12/2002	Lizzi
6,183,502 B1	2/2001	Takeuchi	6,491,657 B2	12/2002	Rowe
6,183,773 B1	2/2001	Anderson	6,500,121 B1	12/2002	Slayton
6,190,323 B1	2/2001	Dias	6,500,141 B1	12/2002	Irion
6,190,336 B1	2/2001	Duarte	6,506,171 B1	1/2003	Vitek et al.
6,193,658 B1	2/2001	Wendelken	6,508,774 B1	1/2003	Acker
6,210,327 B1	4/2001	Brackett et al.	6,511,427 B1	1/2003	Sliwa, Jr. et al.
6,213,948 B1	4/2001	Barthe	6,511,428 B1	1/2003	Azuma
6,216,029 B1	4/2001	Paltieli	6,514,244 B2	2/2003	Pope
6,233,476 B1	5/2001	Strommer et al.	6,517,484 B1	2/2003	Wilk
6,234,990 B1	5/2001	Rowe et al.	6,524,250 B1	2/2003	Weber
6,241,753 B1 *	6/2001	Knowlton A61B 18/12 128/898	6,540,679 B2	4/2003	Slayton
6,246,898 B1	6/2001	Vesely et al.	6,540,685 B1	4/2003	Rhoads et al.
6,251,074 B1	6/2001	Averkiou et al.	6,540,700 B1	4/2003	Fujimoto et al.
6,251,088 B1	6/2001	Kaufman et al.	6,547,788 B1	4/2003	Maguire et al.
6,268,405 B1	7/2001	Yao	6,554,771 B1	4/2003	Buil et al.
			6,569,099 B1	5/2003	Babaev
			6,569,108 B2	5/2003	Sarvazyan et al.
			6,572,552 B2	6/2003	Fukukita
			6,575,956 B1	6/2003	Brisken et al.
			6,595,934 B1	7/2003	Hissong
			6,599,256 B1	7/2003	Acker
			6,605,080 B1	8/2003	Altshuler et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

6,607,498	B2	8/2003	Eshel	7,311,679	B2	12/2007	Desilets et al.
6,618,620	B1	9/2003	Freundlich et al.	7,327,071	B2	2/2008	Nishiyama et al.
6,623,430	B1	9/2003	Slayton	7,331,951	B2	2/2008	Eshel et al.
6,626,854	B2	9/2003	Friedman	7,332,985	B2	2/2008	Larson et al.
6,626,855	B1	9/2003	Weng	7,338,434	B1	3/2008	Haarstad et al.
6,638,226	B2	10/2003	He et al.	7,347,855	B2	3/2008	Eshel
6,645,150	B2	11/2003	Angelsen et al.	RE40,403	E	6/2008	Cho et al.
6,645,162	B2	11/2003	Friedman	7,393,325	B2	7/2008	Barthe
6,662,054	B2	12/2003	Kreindel	7,398,116	B2	7/2008	Edwards
6,663,627	B2	12/2003	Francischelli	7,399,279	B2	7/2008	Abend et al.
6,665,806	B1	12/2003	Shimizu	7,491,171	B2	2/2009	Barthe et al.
6,666,835	B2	12/2003	Martin	7,507,235	B2	3/2009	Keogh et al.
6,669,638	B1	12/2003	Miller	7,510,536	B2	3/2009	Foley et al.
6,685,639	B1	2/2004	Wang et al.	7,517,315	B2	4/2009	Willis
6,685,640	B1	2/2004	Fry	7,530,356	B2	5/2009	Slayton
6,692,450	B1	2/2004	Coleman	7,530,958	B2	5/2009	Slayton
6,699,237	B2	3/2004	Weber	7,532,201	B2	5/2009	Quistgaard et al.
6,716,184	B2	4/2004	Vaezy et al.	7,571,336	B2	8/2009	Barthe
6,719,449	B1	4/2004	Laughlin	7,601,120	B2	10/2009	Moilanen et al.
6,719,694	B2	4/2004	Weng	7,615,015	B2	11/2009	Coleman
6,726,627	B1	4/2004	Lizzi et al.	7,615,016	B2	11/2009	Barthe
6,733,449	B1	5/2004	Krishnamurthy et al.	7,652,411	B2	1/2010	Crunkilton et al.
6,749,624	B2	6/2004	Knowlton	7,662,114	B2	2/2010	Seip et al.
6,772,490	B2	8/2004	Toda	7,674,257	B2	3/2010	Pless et al.
6,773,409	B2	8/2004	Truckai et al.	7,686,763	B2	3/2010	Vaezy et al.
6,775,404	B1	8/2004	Pagoulatos et al.	7,694,406	B2	4/2010	Wildes et al.
6,790,187	B2	9/2004	Thompson et al.	7,695,437	B2	4/2010	Quistgaard et al.
6,824,516	B2	11/2004	Batten et al.	7,713,203	B2	5/2010	Lacoste et al.
6,835,940	B2	12/2004	Morikawa et al.	7,727,156	B2	6/2010	Angelsen et al.
6,846,290	B2	1/2005	Lizzi et al.	7,758,524	B2	7/2010	Barthe
6,875,176	B2	4/2005	Mourad	7,766,848	B2	8/2010	Desilets et al.
6,882,884	B1	4/2005	Mosk et al.	7,789,841	B2	9/2010	Huckle et al.
6,887,239	B2	5/2005	Elstrom	7,806,839	B2	10/2010	Mast et al.
6,889,089	B2	5/2005	Behl	7,815,570	B2	10/2010	Eshel et al.
6,896,657	B2	5/2005	Willis	7,819,826	B2	10/2010	Diederich et al.
6,902,536	B2	6/2005	Manna	7,824,348	B2	11/2010	Barthe
6,905,466	B2	6/2005	Salgo	7,828,734	B2	11/2010	Azhari et al.
6,918,907	B2	7/2005	Kelly	7,833,162	B2	11/2010	Hasegawa et al.
6,920,883	B2	7/2005	Besette	7,841,984	B2	11/2010	Cribbs et al.
6,921,371	B2	7/2005	Wilson	7,846,096	B2	12/2010	Mast et al.
6,932,771	B2	8/2005	Whitmore	7,857,773	B2	12/2010	Desilets et al.
6,932,814	B2	8/2005	Wood	7,875,023	B2	1/2011	Eshel et al.
6,936,044	B2	8/2005	McDaniel	7,901,359	B2	3/2011	Mandrusov et al.
6,936,046	B2	8/2005	Hissong	7,905,007	B2	3/2011	Calisti et al.
6,945,937	B2	9/2005	Culp et al.	7,905,844	B2	3/2011	Desilets et al.
6,948,843	B2	9/2005	Laugharn et al.	7,914,453	B2	3/2011	Slayton et al.
6,953,941	B2	10/2005	Nakano et al.	7,914,469	B2	3/2011	Torbati
6,958,043	B2	10/2005	Hissong	7,931,611	B2	4/2011	Novak et al.
6,971,994	B1	12/2005	Young et al.	7,955,262	B2	6/2011	Rosenberg
6,974,417	B2	12/2005	Lockwood	7,955,281	B2	6/2011	Pedersen et al.
6,976,492	B2	12/2005	Ingle	7,967,764	B2	6/2011	Lidgren et al.
6,992,305	B2	1/2006	Maezawa et al.	7,967,839	B2	6/2011	Flock et al.
6,997,923	B2	2/2006	Anderson	7,993,289	B2	8/2011	Quistgaard et al.
7,006,874	B2	2/2006	Knowlton	8,057,389	B2	11/2011	Barthe et al.
7,020,528	B2	3/2006	Neev	8,057,465	B2	11/2011	Sliwa, Jr. et al.
7,022,089	B2	4/2006	Ooba	8,066,641	B2	11/2011	Barthe et al.
7,058,440	B2	6/2006	Heuscher et al.	8,123,707	B2	2/2012	Huckle et al.
7,063,666	B2	6/2006	Weng	8,128,618	B2	3/2012	Gliklich et al.
7,070,565	B2	7/2006	Vaezy et al.	8,133,180	B2	3/2012	Slayton et al.
7,074,218	B2	7/2006	Washington et al.	8,133,191	B2	3/2012	Rosenberg et al.
7,094,252	B2	8/2006	Koop	8,142,200	B2	3/2012	Crunkilton et al.
7,108,663	B2	9/2006	Talish et al.	8,152,904	B2	4/2012	Slobodzian et al.
7,115,123	B2	10/2006	Knowlton	8,162,858	B2	4/2012	Manna et al.
7,122,029	B2	10/2006	Koop et al.	8,166,332	B2	4/2012	Barthe et al.
7,142,905	B2	11/2006	Slayton	8,182,428	B2	5/2012	Angelsen et al.
7,165,451	B1	1/2007	Brooks et al.	8,197,409	B2	6/2012	Foley et al.
7,179,238	B2	2/2007	Hissong	8,206,299	B2	6/2012	Foley et al.
7,189,230	B2	3/2007	Knowlton	8,208,346	B2	6/2012	Crunkilton
7,229,411	B2	6/2007	Slayton	8,211,017	B2	7/2012	Foley et al.
7,235,592	B2	6/2007	Muratoglu	8,262,591	B2	9/2012	Pedersen et al.
7,258,674	B2	8/2007	Cribbs	8,262,650	B2	9/2012	Zanelli et al.
7,273,459	B2	9/2007	Desilets	8,264,126	B2	9/2012	Toda et al.
7,294,125	B2	11/2007	Phalen et al.	8,273,037	B2	9/2012	Kreindel et al.
7,297,117	B2	11/2007	Trucco	8,282,554	B2	10/2012	Makin et al.
7,303,555	B2	12/2007	Makin et al.	8,292,835	B1	10/2012	Cimino
				8,298,163	B1	10/2012	Cimino
				8,333,700	B1	12/2012	Barthe et al.
				8,334,637	B2	12/2012	Crunkilton et al.
				8,337,407	B2	12/2012	Quistgaard et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

8,343,051 B2	1/2013	Desilets et al.	2002/0082589 A1	6/2002	Friedman
8,366,622 B2	2/2013	Slayton et al.	2002/0087080 A1	7/2002	Slayton
8,388,535 B2	3/2013	Weng et al.	2002/0095143 A1	7/2002	Key
8,409,097 B2	4/2013	Slayton et al.	2002/0099094 A1	7/2002	Anderson
8,425,435 B2	4/2013	Wing et al.	2002/0115917 A1	8/2002	Honda et al.
8,444,562 B2	5/2013	Barthe et al.	2002/0128639 A1	9/2002	Pless et al.
8,454,540 B2	6/2013	Eshel et al.	2002/0128648 A1	9/2002	Weber
8,460,193 B2	6/2013	Barthe et al.	2002/0143252 A1	10/2002	Dunne et al.
8,480,585 B2	7/2013	Slayton et al.	2002/0156400 A1	10/2002	Babaev
8,506,486 B2	8/2013	Slayton et al.	2002/0161357 A1	10/2002	Anderson
8,512,250 B2	8/2013	Quistgaard et al.	2002/0165529 A1	11/2002	Danek
8,523,775 B2	9/2013	Barthe et al.	2002/0168049 A1	11/2002	Schriever
8,535,228 B2	9/2013	Slayton et al.	2002/0169394 A1	11/2002	Eppstein et al.
8,570,837 B2	10/2013	Toda et al.	2002/0169442 A1	11/2002	Neev
8,573,392 B2	11/2013	Bennett et al.	2002/0173721 A1	11/2002	Grunwald et al.
8,583,211 B2	11/2013	Salomir et al.	2002/0193784 A1	12/2002	McHale et al.
8,585,618 B2	11/2013	Hunziker et al.	2002/0193831 A1	12/2002	Smith
8,604,672 B2	12/2013	Toda et al.	2003/0009153 A1	1/2003	Brisken et al.
8,622,937 B2	1/2014	Weng et al.	2003/0014039 A1	1/2003	Barzell et al.
8,636,665 B2	1/2014	Slayton et al.	2003/0018255 A1	1/2003	Martin
8,641,622 B2	2/2014	Barthe et al.	2003/0018270 A1	1/2003	Makin et al.
8,663,112 B2	3/2014	Slayton et al.	2003/0023283 A1 *	1/2003	McDaniel A61K 8/02 607/88
8,672,848 B2	3/2014	Slayton et al.	2003/0028111 A1	2/2003	Vaezy et al.
8,690,778 B2	4/2014	Slayton et al.	2003/0028113 A1	2/2003	Gilbert et al.
8,690,779 B2	4/2014	Slayton et al.	2003/0032900 A1	2/2003	Ella
8,690,780 B2	4/2014	Slayton et al.	2003/0036706 A1	2/2003	Slayton et al.
8,708,935 B2	4/2014	Barthe et al.	2003/0040739 A1	2/2003	Koop
8,715,186 B2	5/2014	Slayton et al.	2003/0050678 A1	3/2003	Sierra
8,726,781 B2	5/2014	Eckhoff et al.	2003/0055417 A1	3/2003	Truckai et al.
8,728,071 B2	5/2014	Lischinsky et al.	2003/0060736 A1	3/2003	Martin et al.
8,753,295 B2	6/2014	Thierman	2003/0065313 A1	4/2003	Koop
8,758,253 B2	6/2014	Sano et al.	2003/0066708 A1	4/2003	Allison et al.
8,836,203 B2	9/2014	Nobles et al.	2003/0073907 A1	4/2003	Taylor
8,857,438 B2	10/2014	Barthe et al.	2003/0074023 A1	4/2003	Kaplan
8,858,471 B2	10/2014	Barthe et al.	2003/0083536 A1	5/2003	Eshel
8,915,853 B2	12/2014	Barthe et al.	2003/0092988 A1	5/2003	Makin
8,915,854 B2	12/2014	Slayton et al.	2003/0097071 A1	5/2003	Halmann et al.
8,915,870 B2	12/2014	Barthe et al.	2003/0099383 A1	5/2003	Lefebvre
8,920,320 B2	12/2014	Stecco et al.	2003/0125629 A1	7/2003	Ustuner
8,920,324 B2	12/2014	Slayton et al.	2003/0135135 A1	7/2003	Miwa et al.
8,926,533 B2	1/2015	Bockenstedt et al.	2003/0139790 A1	7/2003	Ingle et al.
8,932,224 B2	1/2015	Barthe et al.	2003/0153961 A1	8/2003	Babaev
8,932,238 B2	1/2015	Wing et al.	2003/0171678 A1	9/2003	Batten et al.
8,968,205 B2	3/2015	Zeng et al.	2003/0171701 A1	9/2003	Babaev
9,011,336 B2	4/2015	Slayton et al.	2003/0176790 A1	9/2003	Slayton
9,039,617 B2	5/2015	Slayton et al.	2003/0191396 A1	10/2003	Sanghvi
9,039,619 B2	5/2015	Barthe et al.	2003/0200481 A1	10/2003	Stanley
9,095,697 B2	8/2015	Barthe et al.	2003/0212129 A1	11/2003	Liu et al.
9,114,247 B2	8/2015	Barthe et al.	2003/0212351 A1	11/2003	Hissong
9,272,162 B2	3/2016	Slayton et al.	2003/0212393 A1	11/2003	Knowlton
9,283,409 B2	3/2016	Slayton et al.	2003/0216648 A1	11/2003	Lizzi et al.
9,283,410 B2	3/2016	Slayton et al.	2003/0216795 A1	11/2003	Harth
9,320,537 B2	4/2016	Slayton et al.	2003/0220536 A1	11/2003	Hissong
9,421,029 B2	8/2016	Barthe et al.	2003/0220585 A1	11/2003	Hissong
9,427,600 B2	8/2016	Barthe et al.	2003/0229331 A1	12/2003	Brisken et al.
9,427,601 B2	8/2016	Barthe et al.	2003/0233085 A1	12/2003	Giammarusti
9,440,096 B2	9/2016	Barthe et al.	2003/0236487 A1	12/2003	Knowlton
2001/0009997 A1	7/2001	Pope	2004/0000316 A1	1/2004	Knowlton
2001/0009999 A1	7/2001	Kaufman et al.	2004/0001809 A1	1/2004	Brisken
2001/0014780 A1	8/2001	Martin	2004/0002658 A1	1/2004	Marian, Jr.
2001/0014819 A1	8/2001	Ingle	2004/0002705 A1	1/2004	Knowlton
2001/0031922 A1 *	10/2001	Weng A61B 17/0057 600/439	2004/0010222 A1	1/2004	Nunomura et al.
2001/0039380 A1	11/2001	Larson et al.	2004/0015079 A1	1/2004	Berger et al.
2001/0041880 A1	11/2001	Brisken	2004/0015106 A1	1/2004	Coleman
2002/0000763 A1	1/2002	Jones	2004/0030227 A1	2/2004	Littrup
2002/0002345 A1	1/2002	Marlinghaus	2004/0039312 A1	2/2004	Hillstead
2002/0040199 A1	4/2002	Klopotek	2004/0039418 A1	2/2004	Elstrom
2002/0040442 A1	4/2002	Ishidera	2004/0041563 A1	3/2004	Lewin et al.
2002/0055702 A1	5/2002	Atala	2004/0041880 A1	3/2004	Ikeda et al.
2002/0062077 A1	5/2002	Emmenegger	2004/0042168 A1	3/2004	Yang et al.
2002/0062142 A1	5/2002	Knowlton	2004/0044375 A1	3/2004	Diederich et al.
2002/0072691 A1	6/2002	Thompson et al.	2004/0049134 A1	3/2004	Tosaya et al.
2002/0082528 A1	6/2002	Friedman	2004/0059266 A1	3/2004	Fry
2002/0082529 A1	6/2002	Suorsa et al.	2004/0068186 A1	4/2004	Ishida et al.
			2004/0073079 A1	4/2004	Altshuler et al.
			2004/0073113 A1	4/2004	Salgo
			2004/0073115 A1	4/2004	Horzewski et al.
			2004/0073116 A1	4/2004	Smith

(56)

References Cited

U.S. PATENT DOCUMENTS

2004/0073204	A1	4/2004	Ryan et al.	2006/0116671	A1	6/2006	Slayton
2004/0077977	A1	4/2004	Ella et al.	2006/0122508	A1	6/2006	Slayton
2004/0082857	A1	4/2004	Schonenberger	2006/0122509	A1	6/2006	Desilets
2004/0082859	A1	4/2004	Schaer	2006/0161062	A1	7/2006	Arditi et al.
2004/0102697	A1	5/2004	Evron	2006/0184069	A1	8/2006	Vaitekunas
2004/0105559	A1	6/2004	Aylward et al.	2006/0184071	A1	8/2006	Klopotek
2004/0106867	A1	6/2004	Eshel et al.	2006/0189972	A1	8/2006	Grossman
2004/0122323	A1	6/2004	Vortman et al.	2006/0206105	A1	9/2006	Chopra
2004/0122493	A1	6/2004	Ishibashi et al.	2006/0224090	A1	10/2006	Ostrovsky et al.
2004/0143297	A1	7/2004	Ramsey	2006/0229514	A1	10/2006	Wiener
2004/0152982	A1	8/2004	Hwang et al.	2006/0241440	A1	10/2006	Eshel
2004/0158150	A1	8/2004	Rabiner et al.	2006/0241442	A1	10/2006	Barthe
2004/0186535	A1	9/2004	Knowlton	2006/0241470	A1	10/2006	Novak et al.
2004/0189155	A1	9/2004	Funakubo	2006/0241576	A1	10/2006	Diederich et al.
2004/0206365	A1	10/2004	Knowlton	2006/0250046	A1	11/2006	Koizumi et al.
2004/0210214	A1	10/2004	Knowlton	2006/0282691	A1	12/2006	Barthe
2004/0217675	A1	11/2004	Desilets	2006/0291710	A1	12/2006	Wang et al.
2004/0249318	A1	12/2004	Tanaka	2007/0032784	A1	2/2007	Gilklich et al.
2004/0254620	A1	12/2004	Lacoste	2007/0035201	A1	2/2007	Desilets
2004/0267252	A1	12/2004	Washington et al.	2007/0055154	A1	3/2007	Torbati
2005/0033201	A1	2/2005	Takahashi	2007/0055155	A1	3/2007	Owen et al.
2005/0033316	A1	2/2005	Kertz	2007/0055156	A1	3/2007	Desilets et al.
2005/0038340	A1	2/2005	Vaezy et al.	2007/0065420	A1	3/2007	Johnson
2005/0055018	A1	3/2005	Kreindel	2007/0083120	A1	4/2007	Cain et al.
2005/0055073	A1	3/2005	Weber	2007/0087060	A1	4/2007	Dietrich
2005/0061834	A1	3/2005	Garcia et al.	2007/0088245	A1	4/2007	Babaev et al.
2005/0070961	A1	3/2005	Maki	2007/0088346	A1	4/2007	Mirizzi et al.
2005/0074407	A1	4/2005	Smith	2007/0161902	A1	7/2007	Dan
2005/0080469	A1	4/2005	Larson	2007/0166357	A1	7/2007	Shaffer et al.
2005/0091770	A1	5/2005	Mourad et al.	2007/0167709	A1	7/2007	Slayton
2005/0096542	A1	5/2005	Weng et al.	2007/0208253	A1	9/2007	Slayton
2005/0104690	A1	5/2005	Larson et al.	2007/0219604	A1	9/2007	Yaroslavsky et al.
2005/0113689	A1	5/2005	Gritzky	2007/0219605	A1	9/2007	Yaroslavsky et al.
2005/0131302	A1	6/2005	Poland	2007/0238994	A1	10/2007	Stecco et al.
2005/0137656	A1	6/2005	Malak	2007/0239075	A1	10/2007	Rosenberg
2005/0143677	A1	6/2005	Young et al.	2007/0239077	A1	10/2007	Azhari et al.
2005/0154313	A1	7/2005	Desilets	2007/0239079	A1	10/2007	Manstein et al.
2005/0154314	A1	7/2005	Quistgaard	2007/0239142	A1	10/2007	Altshuler
2005/0154332	A1	7/2005	Zanelli	2008/0015435	A1	1/2008	Cribbs et al.
2005/0154431	A1	7/2005	Quistgaard	2008/0027328	A1	1/2008	Klopotek
2005/0187495	A1	8/2005	Quistgaard	2008/0039724	A1	2/2008	Seip et al.
2005/0191252	A1	9/2005	Mitsui	2008/0071255	A1	3/2008	Barthe
2005/0193451	A1	9/2005	Quistgaard	2008/0086054	A1	4/2008	Slayton
2005/0193820	A1	9/2005	Sheljaskow et al.	2008/0086056	A1	4/2008	Chang et al.
2005/0197681	A1	9/2005	Barolet et al.	2008/0097214	A1	4/2008	Meyers et al.
2005/0228281	A1	10/2005	Nefos	2008/0097253	A1	4/2008	Pedersen et al.
2005/0240127	A1	10/2005	Seip et al.	2008/0114251	A1	5/2008	Weymer et al.
2005/0240170	A1	10/2005	Zhang et al.	2008/0139974	A1	6/2008	Da Silva
2005/0251120	A1	11/2005	Anderson et al.	2008/0146970	A1	6/2008	Litman et al.
2005/0251125	A1	11/2005	Pless et al.	2008/0167556	A1	7/2008	Thompson
2005/0256406	A1	11/2005	Barthe	2008/0183077	A1	7/2008	Moreau-Gobard et al.
2005/0261584	A1	11/2005	Eshel	2008/0183110	A1	7/2008	Davenport et al.
2005/0261585	A1	11/2005	Makin et al.	2008/0188745	A1	8/2008	Chen et al.
2005/0267454	A1	12/2005	Hissong	2008/0194964	A1	8/2008	Randall et al.
2005/0288748	A1	12/2005	Li et al.	2008/0195000	A1	8/2008	Spooner et al.
2006/0004306	A1	1/2006	Altshuler	2008/0200810	A1	8/2008	Buchalter
2006/0020260	A1	1/2006	Dover et al.	2008/0200813	A1	8/2008	Quistgaard
2006/0025756	A1	2/2006	Francischelli	2008/0214966	A1	9/2008	Slayton
2006/0042201	A1	3/2006	Curry	2008/0221491	A1	9/2008	Slayton
2006/0058664	A1	3/2006	Barthe	2008/0223379	A1	9/2008	Stuker et al.
2006/0058671	A1	3/2006	Vitek et al.	2008/0242991	A1	10/2008	Moon et al.
2006/0058707	A1	3/2006	Barthe	2008/0243035	A1	10/2008	Crunkilton
2006/0058712	A1	3/2006	Altshuler et al.	2008/0269608	A1	10/2008	Anderson et al.
2006/0074309	A1	4/2006	Bonnefous	2008/0275342	A1	11/2008	Barthe
2006/0074313	A1	4/2006	Slayton et al.	2008/0281206	A1	11/2008	Bartlett et al.
2006/0074314	A1	4/2006	Slayton	2008/0281236	A1	11/2008	Eshel et al.
2006/0074355	A1	4/2006	Slayton	2008/0281237	A1	11/2008	Slayton
2006/0079816	A1	4/2006	Barthe	2008/0281255	A1	11/2008	Slayton
2006/0079868	A1	4/2006	Makin	2008/0294073	A1	11/2008	Barthe
2006/0084891	A1	4/2006	Barthe	2008/0319356	A1	12/2008	Cain
2006/0089632	A1	4/2006	Barthe	2009/0005680	A1	1/2009	Jones et al.
2006/0089688	A1	4/2006	Panescu	2009/0012394	A1	1/2009	Hobelsberger et al.
2006/0094988	A1	5/2006	Tosaya	2009/0043198	A1	2/2009	Milner et al.
2006/0111744	A1	5/2006	Makin	2009/0043293	A1	2/2009	Pankratov et al.
2006/0116583	A1	6/2006	Ogasawara et al.	2009/0048514	A1	2/2009	Azhari et al.
				2009/0069677	A1	3/2009	Chen et al.
				2009/0093737	A1	4/2009	Chomas et al.
				2009/0156969	A1	6/2009	Santangelo
				2009/0163807	A1	6/2009	Sliwa

(56)

References Cited

U.S. PATENT DOCUMENTS

2009/0171252	A1	7/2009	Bockenstedt et al.
2009/0177122	A1	7/2009	Peterson
2009/0177123	A1	7/2009	Peterson
2009/0182231	A1	7/2009	Barthe et al.
2009/0198157	A1	8/2009	Babaev et al.
2009/0216159	A1	8/2009	Slayton et al.
2009/0226424	A1	9/2009	Hsu
2009/0227910	A1	9/2009	Pedersen et al.
2009/0230823	A1	9/2009	Kushculey et al.
2009/0253988	A1	10/2009	Slayton et al.
2009/0281463	A1	11/2009	Chapelon et al.
2009/0312693	A1	12/2009	Thapliyal et al.
2009/0318909	A1	12/2009	Debenedictis et al.
2009/0326420	A1	12/2009	Moonen et al.
2010/0011236	A1	1/2010	Barthe et al.
2010/0022919	A1	1/2010	Peterson
2010/0022921	A1	1/2010	Seip et al.
2010/0022922	A1	1/2010	Barthe et al.
2010/0030076	A1	2/2010	Vortman et al.
2010/0042020	A1	2/2010	Ben-Ezra
2010/0049178	A1	2/2010	Deem et al.
2010/0056925	A1	3/2010	Zhang et al.
2010/0100014	A1	4/2010	Eshel et al.
2010/0113983	A1	5/2010	Heckerman et al.
2010/0130891	A1	5/2010	Taggart et al.
2010/0160782	A1	6/2010	Slayton et al.
2010/0160837	A1	6/2010	Hunziker et al.
2010/0168576	A1	7/2010	Poland et al.
2010/0191120	A1	7/2010	Kraus et al.
2010/0241035	A1	9/2010	Barthe et al.
2010/0249602	A1	9/2010	Buckley et al.
2010/0249669	A1	9/2010	Ulric et al.
2010/0256489	A1	10/2010	Pedersen et al.
2010/0274161	A1	10/2010	Azhari et al.
2010/0280420	A1	11/2010	Barthe et al.
2010/0286518	A1	11/2010	Lee et al.
2010/0312150	A1	12/2010	Mast et al.
2011/0040171	A1	2/2011	Foley et al.
2011/0040190	A1	2/2011	Jahnke et al.
2011/0066084	A1	3/2011	Desilets et al.
2011/0087099	A1	4/2011	Eshel et al.
2011/0087255	A1	4/2011	McCormack et al.
2011/0112405	A1	5/2011	Barthe et al.
2011/0144490	A1	6/2011	Davis et al.
2011/0178444	A1	7/2011	Slayton et al.
2011/0178541	A1	7/2011	Azhari
2011/0190745	A1	8/2011	Uebelhoer et al.
2011/0251524	A1	10/2011	Azhari et al.
2011/0251527	A1	10/2011	Kushculey et al.
2011/0270137	A1	11/2011	Goren et al.
2011/0319793	A1	12/2011	Hynynen
2012/0004549	A1	1/2012	Barthe et al.
2012/0016239	A1	1/2012	Barthe et al.
2012/0029353	A1	2/2012	Slayton et al.
2012/0035473	A1	2/2012	Sanghvi et al.
2012/0035475	A1	2/2012	Barthe et al.
2012/0035476	A1	2/2012	Barthe et al.
2012/0046547	A1	2/2012	Barthe et al.
2012/0053458	A1	3/2012	Barthe et al.
2012/0111339	A1	5/2012	Barthe et al.
2012/0123304	A1	5/2012	Rybyanets et al.
2012/0136280	A1	5/2012	Rosenberg et al.
2012/0136282	A1	5/2012	Rosenberg et al.
2012/0143056	A1	6/2012	Slayton et al.
2012/0143100	A1	6/2012	Jeong et al.
2012/0165668	A1	6/2012	Slayton et al.
2012/0165848	A1	6/2012	Slayton et al.
2012/0191020	A1	7/2012	Vitek et al.
2012/0197120	A1	8/2012	Makin et al.
2012/0197121	A1	8/2012	Slayton et al.
2012/0209150	A1	8/2012	Zeng et al.
2012/0215105	A1	8/2012	Slayton et al.
2012/0271202	A1	10/2012	Wisdom
2012/0271294	A1	10/2012	Barthe et al.
2012/0296240	A1	11/2012	Azhari et al.
2012/0302883	A1	11/2012	Kong et al.
2012/0316426	A1	12/2012	Foley et al.
2012/0330197	A1	12/2012	Makin et al.
2012/0330222	A1	12/2012	Makin et al.
2012/0330223	A1	12/2012	Makin et al.
2012/0330283	A1	12/2012	Hyde et al.
2012/0330284	A1	12/2012	Hyde et al.
2013/0012755	A1	1/2013	Slayton
2013/0012816	A1	1/2013	Slayton et al.
2013/0012838	A1	1/2013	Jaeger et al.
2013/0012842	A1	1/2013	Barthe
2013/0018285	A1	1/2013	Park et al.
2013/0018286	A1	1/2013	Slayton et al.
2013/0046209	A1	2/2013	Slayton et al.
2013/0051178	A1	2/2013	Rybyanets
2013/0060170	A1	3/2013	Lee et al.
2013/0066208	A1	3/2013	Barthe et al.
2013/0066237	A1	3/2013	Smotrich et al.
2013/0072826	A1	3/2013	Slayton et al.
2013/0096471	A1	4/2013	Slayton et al.
2013/0190659	A1	7/2013	Slayton et al.
2013/0211293	A1	8/2013	Auboiroux et al.
2013/0225994	A1	8/2013	Hsu et al.
2013/0268032	A1	10/2013	Neev
2013/0274603	A1	10/2013	Barthe et al.
2013/0281853	A1	10/2013	Slayton et al.
2013/0281891	A1	10/2013	Slayton et al.
2013/0296697	A1	11/2013	Slayton et al.
2013/0296700	A1	11/2013	Slayton et al.
2013/0303904	A1	11/2013	Barthe et al.
2013/0303905	A1	11/2013	Barthe et al.
2013/0310714	A1	11/2013	Eshel et al.
2013/0310863	A1	11/2013	Makin et al.
2013/0345562	A1	12/2013	Barthe et al.
2014/0024974	A1	1/2014	Slayton et al.
2014/0050054	A1	2/2014	Toda et al.
2014/0081300	A1	3/2014	Melodelima et al.
2014/0082907	A1	3/2014	Barthe et al.
2014/0117814	A1	5/2014	Toda et al.
2014/0142430	A1	5/2014	Slayton et al.
2014/0148834	A1	5/2014	Barthe et al.
2014/0180174	A1	6/2014	Slayton et al.
2014/0187944	A1	7/2014	Slayton et al.
2014/0188015	A1	7/2014	Slayton et al.
2014/0188145	A1	7/2014	Slayton et al.
2014/0194723	A1	7/2014	Herzog et al.
2014/0208856	A1	7/2014	Schmid
2014/0221823	A1	8/2014	Keogh et al.
2014/0236049	A1	8/2014	Barthe et al.
2014/0236061	A1	8/2014	Lee et al.
2014/0243713	A1	8/2014	Slayton et al.
2014/0257145	A1	9/2014	Emery
2014/0276055	A1	9/2014	Barthe et al.
2015/0000674	A1	1/2015	Barthe et al.
2015/0080723	A1	3/2015	Barthe et al.
2015/0080771	A1	3/2015	Barthe et al.
2015/0080874	A1	3/2015	Slayton et al.
2015/0088182	A1	3/2015	Slayton et al.
2015/0164734	A1	6/2015	Slayton et al.
2015/0165238	A1	6/2015	Slayton et al.
2015/0165243	A1	6/2015	Slayton et al.
2015/0174388	A1	6/2015	Slayton
2015/0202468	A1	7/2015	Slayton et al.
2015/0217141	A1	8/2015	Barthe et al.
2015/0360058	A1	12/2015	Barthe et al.
2015/0374333	A1	12/2015	Barthe et al.
2015/0375014	A1	12/2015	Slayton et al.
2016/0027994	A1	1/2016	Toda et al.
2016/0175619	A1	6/2016	Lee et al.
2016/0206335	A1	7/2016	Slayton
2016/0206341	A1	7/2016	Slayton
2016/0256675	A1	9/2016	Slayton
2016/0296769	A1	10/2016	Barthe et al.
FOREIGN PATENT DOCUMENTS			
DE	10140064	3/2003	
DE	10219297	11/2003	
DE	10219217	12/2004	

(56)

References Cited

FOREIGN PATENT DOCUMENTS

DE	20314479	12/2004	KR	1020070065332	6/2007
EP	0142215	5/1984	KR	1020070070161	7/2007
EP	0344773	12/1989	KR	1020070098856	10/2007
EP	1479412	11/1991	KR	1020070104878	10/2007
EP	0473553	4/1992	KR	1020070114105	11/2007
EP	670147	2/1995	KR	1020000059516	4/2012
EP	0661029	7/1995	WO	WO9312742	7/1993
EP	724894	2/1996	WO	WO9524159	9/1995
EP	763371	11/1996	WO	WO9625888	8/1996
EP	1044038	10/2000	WO	WO9634568	11/1996
EP	1050322	11/2000	WO	WO9639079	12/1996
EP	1234566	8/2002	WO	WO9735518	10/1997
EP	1262160	12/2002	WO	WO9832379	7/1998
EP	1283690	2/2003	WO	WO9852465	11/1998
EP	1374944	1/2004	WO	WO9933520	7/1999
EP	1028660	1/2008	WO	WO9949788	10/1999
EP	1874241	1/2008	WO	WO0006032	2/2000
EP	1362223	5/2008	WO	WO0015300	3/2000
EP	1750804	7/2008	WO	WO0021612	4/2000
EP	1811901	4/2009	WO	WO0053113	9/2000
EP	1785164	8/2009	WO	WO0128623	4/2001
EP	2230904	9/2010	WO	WO0145550	6/2001
EP	1501331	6/2011	WO	WO0180709	11/2001
EP	2066405	11/2011	WO	WO0182777	11/2001
EP	2474050	7/2012	WO	WO0182778	11/2001
FR	2532851	9/1983	WO	WO0187161	11/2001
FR	2685872	1/1992	WO	WO0209813	2/2002
FR	2672486	8/1992	WO	WO0215768	2/2002
FR	2703254	3/1994	WO	WO0224050	3/2002
GB	2113099	8/1983	WO	WO02054018	7/2002
IL	102516	1/1996	WO	WO02092168	11/2002
IL	112369	8/1999	WO	WO03053266	7/2003
IL	120079	3/2001	WO	WO03065347	8/2003
JP	63036171	2/1988	WO	WO03070105	8/2003
JP	03048299	3/1991	WO	WO03077833	9/2003
JP	3123559	5/1991	WO	WO03086215	10/2003
JP	03136642	6/1991	WO	WO03096883	11/2003
JP	4089058	3/1992	WO	WO03099177	12/2003
JP	04150847	5/1992	WO	WO03099382	12/2003
JP	7080087	3/1995	WO	WO03101530	12/2003
JP	07505793	6/1995	WO	WO04000116	12/2003
JP	7184907	7/1995	WO	WO2004080147	9/2004
JP	7222782	8/1995	WO	WO2004110558	12/2004
JP	09047458	2/1997	WO	WO2005/011804	2/2005
JP	9108288	4/1997	WO	WO2005065408	7/2005
JP	9503926	4/1997	WO	WO2005090978	9/2005
JP	11123226	5/1999	WO	WO2005113068	12/2005
JP	11505440	5/1999	WO	WO2006/042163	4/2006
JP	11506636	6/1999	WO	WO2006036870	4/2006
JP	10248850	9/1999	WO	WO2006042168	4/2006
JP	2000126310	5/2000	WO	WO2006042201	4/2006
JP	2000166940	6/2000	WO	WO2006065671	6/2006
JP	2000233009	8/2000	WO	WO2006082573	8/2006
JP	2001170068	6/2001	WO	WO2007067563	6/2007
JP	2002505596	2/2002	WO	WO2008036622	3/2008
JP	2002078764	3/2002	WO	WO2008036479	11/2008
JP	2002515786	5/2002	WO	WO2009013729	1/2009
JP	2002521118	7/2002	WO	WO2009149390	10/2009
JP	2002537939	11/2002	WO	WO2008144274	1/2010
JP	2003050298	7/2003	WO	WO2012134645	1/2013
JP	2003204982	7/2003	WO	WO2014045216	3/2014
JP	2004-507280	3/2004	WO	WO2014055708	4/2014
JP	2004-509671	4/2004	WO	WO2014057388	4/2014
JP	2004-512856	4/2004			
JP	2004147719	5/2004			
JP	2005503388	2/2005			
JP	2005527336	9/2005			
JP	2005323213	11/2005			
JP	2006520247	9/2006			
JP	2008515559	5/2008			
JP	2009518126	5/2009			
JP	2010517695	5/2010			
KR	1020010024871	3/2001			
KR	100400870	10/2003			
KR	1020060113930	11/2006			

OTHER PUBLICATIONS

- Alam, M., "The future of noninvasive procedural dermatology". *Semin Cutan Med Surg.* Mar. 2013; 32(1):59-61.
- Alam, M., et al., "Ultrasound tightening of facial and neck skin: a rater-blinded prospective cohort study". *J Am Acad Dermatol.* 2010. 62(2): p. 262-9.
- Alexiades-Armenakas, M., "Ultrasound Technologies for Dermatologic Techniques". *J Drugs Derm.* 2014. 12 (11): p. 1305.
- Alster, T.S., et al., "Noninvasive lifting of arm, thigh, and knee skin with transcutaneous intense focused ultrasound". *Dermatol Surg.* 2012. 38(5): p. 754-9.
- Alster, Tinas S., Tanzi, Elizabeth L., "Cellulite Treatment using a Novel Combination Radiofrequency, Infrared Light, and Mechani-

(56)

References Cited

OTHER PUBLICATIONS

- cal Tissue Manipulation Device,” *Journal of Cosmetic & Laser Therapy*, Jun. 2005, vol. 7, Issue 2, pp. 81-85.
- Arosarena, O., “Options and Challenges for Facial Rejuvenation in Patients With Higher Fitzpatrick Skin Phototypes”. *JAMA Facial Plastic Surgery*, 2015.
- Arthur et al., “Non-invasive estimation of hyperthermia temperatures with ultrasound,” *Int. J. Hyperthermia*, Sep. 2005, 21(6), pp. 589-600.
- Barthe et al., “Ultrasound therapy system and ablation results utilizing miniature imaging/therapy arrays,” *Ultrasonics Symposium, 2004 IEEE*, Aug. 23, 2004, pp. 1792-1795, vol. 3.
- Bozec, Laurent et al., *Thermal Denaturation Studies of Collagen by Microthermal Analysis and Atomic Force Microscopy*, *Biophysical Journal*, vol. 101, pp. 228-236. (Jul. 2001).
- Brobst, R.W., et. al., “Noninvasive Treatment of the Neck”. *Facial Plast Surg Clin North Am*, 2014, 22(2): p. 191-202.
- Brobst, R.W., et., al., “Ulthera: initial and six month results”. *Facial Plast Surg Clin North Am*, 2012, 20(2): p. 163-76.
- Calderhead et al., “One Mechanism Behind LED Photo-Therapy for Wound Healing and Skin Rejuvenation: Key Role of the Mast Cell” *Laser Therapy* 17.3: 141-148 (2008).
- Casabona, G., et. al., “Microfocused Ultrasound With Visualization and Fillers for Increased Neocollagenesis: Clinical and Histological Evaluation”. *Dermatol Surg* 2014;40:S194-S198.
- Chan, N.P., et al., “Safety study of transcutaneous focused ultrasound for non-invasive skin tightening in Asians”. *Lasers Surg Med*, 2011, 43(5): p. 366-75.
- Chapelon et al., “Effects of Cavitation in the High Intensity Therapeutic Ultrasound”, *Ultrasonics Symposium—1357* (1991).
- Chapelon, et al., “Thresholds for Tissue Ablation by Focused Ultrasound” (1990).
- Chen, L. et al., “Effect of Blood Perfusion on the ablation of liver parenchyma with high intensity focused ultrasound,” *Phys. Med. Biol.*; 38:1661-1673; 1993b.
- Coon, Joshua et al., “Protein identification using sequential ion/ion reactions and tandem mass spectrometry” *Proceedings of the National Academy of Sciences of the USA*, vol. 102, No. 27, Jul. 27, 2005, pp. 9463-9468.
- Corry, Peter M., et al., “Human Cancer Treatment with Ultrasound”, *IEEE Transactions on Sonics and Ultrasonics*, vol. SU-31, No. 5, Sep. 1984, pp. 444, 456.
- Damianou et al., “Application of the Thermal Dose Concept for Predicting the Necrosed Tissue Volume During Ultrasound Surgery,” 1993 *IEEE Ultrasound Symposium*, pp. 1199-1202.
- Daum et al., Design and Evaluation of a Feedback Based Phased Array System for Ultrasound Surgery, *IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control*, vol. 45, No. 2, Mar. 1998, pp. 431-438.
- Davis, Brian J., et al., “An Acoustic Phase Shift Technique for the Non-Invasive Measurement of Temperature Changes in Tissues”, 1985 *Ultrasonics Symposium*, pp. 921-924.
- Dayan, S.H., et al., “Prospective, Multi-Center, Pivotal Trial Evaluating the Safety and Effectiveness of Micro-Focused Ultrasound with Visualization (MFU-V) for Improvement in Lines and Wrinkles of the Decolletage”. *Plast Reconstr Surg*. Oct. 2014; 134(4 Suppl 1):123-4.
- Decision of the Korean Intellectual Property Tribunal dated Jun. 28, 2013 regarding Korean Patent No. 10-1142108, which is related to the pending application and/or an application identified in the Table on pp. 1-4 of the Information Disclosure Statement herein (English translation, English translation certification, and Korean decision included).
- Dierickx, Christine C., “The Role of Deep Heating for Noninvasive Skin Rejuvenation” *Lasers in Surgery and Medicine* 38:799-807 (2006).
- Dobke, M.K., et al., “Tissue restructuring by energy-based surgical tools”. *Clin Plast Surg*, 2012, 39(4): p. 399-408.
- Dong, Yuan-Lin et al., “Effect of Ibuprofen on the Inflammatory Response to Surgical Wounds” *The Journal of Trauma*, vol. 35, No. 3. (1993).
- Dvivedi, Sanjay, et al. “Effect of Ibuprofen and diclofenac sodium on experimental wound healing” *Indian Journal of Experimental Biology*, vol. 35, pp. 1243-1245. (Nov. 1997).
- Fabi, S.G., “Microfocused Ultrasound With Visualization for Skin Tightening and Lifting: My Experience and a Review of the Literature”. *Dermatol Surg*. Dec. 2014; 40 Suppl 12:S164-7.
- Fabi, S.G., “Noninvasive skin tightening: focus on new ultrasound techniques”. *Clin Cosmet Investig Dermatol*. Feb. 5, 2015; 8:47-52.
- Fabi, S.G., et. al., “A prospective multicenter pilot study of the safety and efficacy of microfocused ultrasound with visualization for improving lines and wrinkles of the décolleté”. *Dermatol Surg*. Mar. 2015; 41(3):327-35.
- Fabi, S.G., et. al., “Evaluation of microfocused ultrasound with visualization for lifting, tightening, and wrinkle reduction of the décolletage”. *J Am Acad Dermatol*, 2013, 69(6): p. 965-71.
- Fabi, S.G., et. al., “Future directions in cutaneous laser surgery”. *Dermatol Clin*, 2014, 32(1): p. 61-9.
- Fabi, S.G., et. al., “Retrospective Evaluation of Micro-focused Ultrasound for Lifting and Tightening the Face and Neck”. *Dermatol Surg*, 2014.
- Friedmann D.P., “Comments on evaluation of microfocused ultrasound system for improving skin laxity and tightening in the lower face”. *Aesthet Surg J*. Mar. 2015;35(3):NP81-2.
- Friedmann, D.P., et. al., “Combination of intense pulsed light, Sculptra, and Ultherapy for treatment of the aging face”. *J Cosmet Dermatol*, 2014, 13(2): p. 109-18.
- Fry, W.J. et al., “Production of Focal Destructive Lesions in the Central Nervous System with Ultrasound,” *J. Neurosurg.*, 11:471-478; 1954.
- Fujimoto, et al., “A New Cavitation Suppression Technique for Local Ablation Using High-Intensity Focused Ultrasound” *Ultrasonics Symposium—1629* (1995).
- Gliklich et al., Clinical Pilot Study of Intense Ultrasound therapy to Deep Dermal Facial Skin and Subcutaneous Tissues, *Arch Facial Plastic Surgery*, Mar. 1, 2007, vol. 9, No. 1.
- Gold, M.H., et. al., “Use of Micro-Focused Ultrasound with Visualization to Lift and Tighten Lax Knee Skin”. *J Cosmet Laser Ther*, 2014: p. 1-15.
- Goldberg, D.J., et. al., “Safety and Efficacy of Microfocused Ultrasound to Lift, Tighten, and Smooth the Buttocks”. *Dermatol Surg* 2014; 40:1113-1117.
- Greene, R.M., et al., “Skin tightening technologies”. *Facial Plast Surg*. Feb. 2014; 30(1):62-7.
- Greenhalgh, David G., “Wound healing and diabetes mellitus” *Clinics in Plastic Surgery* 30; 37-45. (2003).
- Guo, S. et al., “Factors Affecting Wound Healing” *Critical Reviews in Oral Biology & Medicine*, *J Dent Res* 89(3), pp. 219-229. (2010).
- Haar, G.R. et al., “Tissue Destruction with Focused Ultrasound in Vivo,” *Eur. Urol.* 23 (suppl. 1):8-11; 1993.
- Hantash, Basil M. et al., “Bipolar Fractional Radiofrequency Treatment Induces Neocollagenesis and Neocollagenesis” *Lasers in Surgery and Medicine* 41:1-9 (2009).
- Hantash, Basil M. et al., “In Vivo Histological Evaluation of a Novel Ablative Fractional Resurfacing Device” *Lasers in Surgery and Medicine* 39:96-107 (2007).
- Harris, M.O., “Safety of Microfocused Ultrasound With Visualization in Patients With Fitzpatrick Skin Phototypes III to VI”. *JAMA Facial Plast. Surg*, 2015.
- Hart, et. al., “Current Concepts in the Use of PLLA:Clinical Synergy Noted with Combined Use of Microfocused Ultrasound and Poly-L-Lactic Acid on the Face, Neck, and Décolletage”. *Amer. Soc. Plast. Surg*. 2015. 136; 180-187S.
- Hassan et al., “Structure and Applications of Poly(vinyl alcohol) Hydrogels Produced by Conventional Crosslinking or by Freezing/Thawing Methods,” *advanced in Polymer Science*, 2000, pp. 37-65, vol. 153.
- Hassan et al., “Structure and Morphology of Freeze/Thawed PVA Hydrogels,” *Macromolecules*, Mar. 11, 2000, pp. 2472-2479, vol. 33, No. 7.

(56)

References Cited

OTHER PUBLICATIONS

- Hitchcock, T.M. et. al., "Review of the safety profile for microfocused ultrasound with Visualization". *Journal of Cosmetic Dermatology*, 13, 329-335. (2014).
- Husseini et al., "The Role of Cavitation in Acoustically Activated Drug Delivery," *J. Control Release*, Oct. 3, 2005, pp. 253-261, vol. 107(2).
- Husseini et al. "Investigating the mechanism of acoustically activated uptake of drugs from Pluronic micelles," *BMD Cancer* 2002, 2:20k, Aug. 30, 2002, pp. 1-6.
- Hynynen et al., "Temperature Distributions During Local Ultrasound Induced Hyperthermia In Vivo," *Ultrasonics Symposium—745* (1982).
- Jeffers et al., "Evaluation of the Effect of Cavitation Activity on Drug-Ultrasound Synergisms," 1993 IEEE Ultrasonics Symposium, pp. 925-928.
- Jenne, J., et al., "Temperature Mapping for High Energy US-Therapy", 1994 Ultrasonics Symposium, pp. 1879-1882.
- Jeong, K.H., et al., "Neurologic complication associated with intense focused ultrasound". *J Cosmet Laser Ther*, 2013.
- Johnson, S.A., et al., "Non-Intrusive Measurement of Microwave and Ultrasound-Induced Hyperthermia by Acoustic Temperature Tomography", *Ultrasonics Symposium Proceedings*, pp. 977-982. (1977).
- Kim, H.J., et al., "Coagulation and ablation patterns of high-intensity focused ultrasound on a tissue mimicking phantom and cadaveric skin". *Laser Med Sci. Sep.* 4, 2015.
- Kornstein, A.N., "Ulthera for silicone lip correction". *Plast Reconstr Surg*, 2012. 129(6): p. 1014e-1015e.
- Kornstein, A.N., "Ultherapy shrinks nasal skin after rhinoplasty following failure of conservative measures". *Plast Reconstr Surg*, 2013. 131(4): p. 664e-6e.
- Krischak, G.D., et al., "The effects of non-steroidal anti-inflammatory drug application on incisional wound healing in rats" *Journal of Wound Care*, vol. 6, No. 2, (Feb. 2007).
- Laubach, H.J., et. al., "Confined Thermal Damage with Intense Ultrasound (IUS)" [abstr.] *American Society for Laser Medicine and Surgery Abstracts*, p. 15 #43 (Apr. 2006).
- Laubach, H.J., et. al., "Intense focused ultrasound: evaluation of a new treatment modality for precise microcoagulation within the skin". *Dermatol Surg*, 2008. 34(5): p. 727-34.
- Lee, H.J., et. al., "The efficacy and safety of intense focused ultrasound in the treatment of enlarged facial pores in Asian skin". *J Dermatolog Treat*, 2014.
- Lee, H.S., et. al., "Multiple Pass Ultrasound Tightening of Skin Laxity of the Lower Face and Neck". *Dermatol Surg*, 2011.
- Lin, Sung-Jan, et al., "Monitoring the thermally induced structural transitions of collagen by use of second-harmonic generation microscopy" *Optics Letters*, vol. 30, No. 6, (Mar. 15, 2005).
- MacGregor J.L., et. al., "Microfocused Ultrasound for Skin Tightening". *Semin Cutan Med Surg* 32:18-25. (2013).
- Madersbacher, S. et al., "Tissue Ablation in Benign Prostatic Hyperplasia with High Intensity Focused Ultrasound," *Dur. Urol.*, 23 (suppl. 1):39-43; 1993.
- Makin et al, "B-Scan Imaging and Thermal Lesion Monitoring Using Miniaturized Dual-Functionality Ultrasound Arrays," *Ultrasonics Symposium*, 2004 IEEE, Aug. 23, 2004, pp. 1788-1791, vol. 3.
- Makin et al, "Confirmed Bulk Ablation and Therapy Monitoring Using Intracorporeal Image-Treat Ultrasound Arrays," 4th International Symposium on Therapeutic Ultrasound, Sep. 19, 2004.
- Makin et al., "Miniaturized Ultrasound Arrays for Interstitial Ablation and Imaging," *UltraSound Med. Biol.* 2005, Nov. 1, 2005, pp. 1539-1550, vol. 31(11).
- Manohar et al, "Photoacoustic mammography laboratory prototype: imaging of breast tissue phantoms," *Journal of Biomedical Optics*, Nov./Dec. 2004, pp. 1172-1181, vol. 9, No. 6.
- Mast et al, "Bulk Ablation of Soft Tissue with Intense Ultrasound; Modeling and Experiments," *J. Acoust. Soc. Am.*, Oct. 1, 2005, pp. 2715-2724, vol. 118(4).
- Meshkinpour, Azin, et al., "Treatment of Hypertrophic Scars and Keloids With a Radiofrequency Device: A Study of Collagen Effects" *Lasers in Surgery and Medicine* 37:343-349 (2005).
- Minkis, K., et. al., "Ultrasound skin tightening". *Dermatol Clin*, 2014. 32(1): p. 71-7.
- Mitragotri, S., "Healing sound: the use of ultrasound in drug delivery and other therapeutic applications," *Nature Reviews; Drug Delivery*, pp. 255-260, vol. 4 (Mar. 2005).
- Mosser, David M. et al., "Exploring the full spectrum of macrophage activation" *Nat Rev Immunol*; 8(12): 958-969. (Dec. 2008).
- Murota, Sei-Itsu, et al., "Stimulatory Effect of Prostaglandins on the Production of Hexosamine-Containing Substances by Cultured Fibroblasts (3) Induction of Hyaluronic Acid Synthetase by Prostaglandin" Department of Pharmacology, Tokyo Metropolitan Institute of Gerontology, Itabashiku, Tokyo-173, Japan. (Nov. 1977, vol. 14, No. 5).
- Murota, Sei-Itsu, et al., "The Stimulatory Effect of Prostaglandins on Production of Hexosamine-Containing Substances by Cultured Fibroblasts" Department of Pharmacology, Tokyo Metropolitan Institute of Gerontology, Itabashiku, Tokyo-173, Japan. (Aug. 1976, vol. 12, No. 2).
- Nestor, M.S. et. al., "Safety and Efficacy of Micro-focused Ultrasound Plus Visualization for the Treatment of Axillary Hyperhidrosis". *J Clin Aesthet Dermatol*, 2014. 7(4): p. 14-21.
- Oni, G., et. al. "Response to 'comments on evaluation of microfocused ultrasound system for improving skin laxity and tightening in the lower face'". *Aesthet Surg J. Mar.* 2015;35(3):NP83-4.
- Oni, G., et. al., "Evaluation of a Microfocused Ultrasound System for Improving Skin Laxity and Tightening in the Lower Face". *Aesthet Surg J*, 2014. 38:861-868.
- Pak, C.S., et. al., "Safety and Efficacy of Ulthera in the Rejuvenation of Aging Lower Eyelids: A Pivotal Clinical Trial". *Aesthetic Plast Surg*, 2014.
- Paradossi et al., "Poly(vinyl alcohol) as versatile biomaterial for potential biomedical applications," *Journal of Materials Science: Materials in Medicine*, 2003, pp. 687-691, vol.
- Pritzker, R.N., et. al., "Updates in noninvasive and minimally invasive skin tightening". *Semin Cutan Med Surg*. Dec. 2014;33(4):182-7.
- Pritzker, R.N., et. al., "Comparison of different technologies for noninvasive skin tightening". *Journal of Cosmetic Dermatology*, 13, 315-323. (2014).
- Rappolee, Daniel A., et al., "Wound Macrophages Express TGF and Other Growth Factors in Vivo: Analysis by mRNA Phenotyping" *Science*, vol. 241, No. 4866 (Aug. 1988).
- Reid, Gavin, et al., "Tandem Mass spectrometry of ribonuclease A and B: N-linked glycosylation site analysis of whole protein ions," *Analytical Chemistry*. Feb. 1, 2002, vol. 74, No. 3, pp. 577-583.
- Righetti et al, "Elastographic Characterization of HIFU-Induced Lesions in Canine Livers," 1999, *Ultrasound in Med & Bio*, vol. 25, No. 7, pp. 1099-1113.
- Rokhsar, C., et. al., "Safety and efficacy of microfocused ultrasound in tightening of lax elbow skin". *Dermatol Surg*. 2015; 41(7):821-6.
- Rosenberg, Carol S. "Wound Healing in the Patient with Diabetes Mellitus" *Nursing Clinics of North America*, vol. 25, No. 1, (Mar. 1990).
- Saad et al., "Ultrasound-Enhanced Effects of Adriamycin Against Murine Tumors," *Ultrasound in Med. & Biol.* vol. 18, No. 8, pp. 715-723 (1992).
- Sabet-Peyman, E.J. et. al., "Complications Using Intense Ultrasound Therapy to Treat Deep Dermal Facial Skin and Subcutaneous Tissues". *Dermatol Surg* 2014; 40:1108-1112.
- Sandulache, Vlad C. et al., "Prostaglandin E2 inhibition of keloid fibroblast migration, contraction, and transforming growth factor (TGF)- β 1-induced collagen synthesis" *Wound Rep Reg* 15 122-133, 2007. (2007).
- Sanghvi, N.T., et al., "Transrectal Ablation of Prostate Tissue Using Focused Ultrasound," 1993 *Ultrasonics Symposium*, IEEE, pp. 1207-1210.
- Sasaki, G.H. et. al., "Clinical Efficacy and Safety of Focused-Image Ultrasonography: A 2-Year Experience". *Aesthet Surg J*, 2012.

(56)

References Cited

OTHER PUBLICATIONS

- Sasaki, G.H. et al., "Microfocused Ultrasound for Nonablative Skin and Subdermal Tightening to the Periorbitum and Body Sites: Preliminary Report on Eighty-Two Patients". *Journal of Cosmetics, Dermatological Sciences and Applications*, 2012, 2, 108-116.
- Sassen, Sander, "ATI's R520 architecture, the new king of the hill?" <http://www.hardwareanalysis.com/content/article/1813>, Sep. 16, 2005, 2 pages.
- Seip, Ralf, et al., "Noninvasive Detection of Thermal Effects Due to Highly Focused Ultrasonic Fields," *IEEE Symposium*, pp. 1229-1232, vol. 2, Oct. 3-Nov. 1993.
- Seip, Ralf, et al., "Noninvasive Estimation of Tissue Temperature Response to Heating Fields Using Diagnostic Ultrasound," *IEEE Transactions on Biomedical Engineering*, vol. 42, No. 8, Aug. 1995, pp. 828-839.
- Simon et al., "Applications of Lipid-Coated Microbubble Ultrasonic Contrast to Tumor Therapy," *Ultrasound in Med. & Biol.* vol. 19, No. 2, pp. 123-125 (1993).
- Sklar, L.R., et al., "Use of transcutaneous ultrasound for lipolysis and skin tightening: a review". *Aesthetic Plast Surg*, 2014. 38(2): p. 429-41.
- Smith, Nadine Barrie, et al., "Non-invasive In Vivo Temperature Mapping of Ultrasound Heating Using Magnetic Resonance Techniques", 1994 *Ultrasonics Symposium*, pp. 1829-1832, vol. 3.
- Suh, D.H., et al., "A intense-focused ultrasound tightening for the treatment of infraorbital laxity". *J Cosmet Laser Ther*, 2012. 14(6): p. 290-5.
- Suh, D.H., et al., "Comparative histometric analysis of the effects of high-intensity focused ultrasound and radiofrequency on skin". *J Cosmet Laser Ther*. Mar. 2015 24:1-7.
- Suh, D.H., et al., "Intense Focused Ultrasound Tightening in Asian Skin: Clinical and Pathologic Results" *American Society for Dermatologic Surgery, Inc.*; 37:1595-1602. (2011).
- Suh, D.H., et al., "Intense focused ultrasound tightening in asian skin: clinical and pathologic results". *Dermatol Surg*, 2011. 37(11): p. 1595-602.
- Surry et al., "Poly(vinyl alcohol) cryogel phantoms for use in ultrasound and MR imaging," *Phys. Med. Biol.*, Dec. 6, 2004, pp. 5529-5546, vol. 49.
- Syka J. E. P. et al., "Peptide and Protein Sequence Analysis by Electron Transfer Dissociation Mass Spectrometry," *Proceedings of the National Academy of Sciences of USA, National Academy of Science, Washington, DC*, vol. 101, No. 26, Jun. 29, 2004, pp. 9528-9533.
- Talbert, D. G., "An Add-On Modification for Linear Array Real-Time Ultrasound Scanners to Produce 3D Displays," *UTS Int'l 1977 Brighton, England (Jun. 28-30, 1977)* pp. 57-67.
- Tata et al., "Interaction of Ultrasound and Model Membrane Systems: Analyses and Predictions," *American Chemical Society, Phys. Chem.* 1992, 96, pp. 3548-3555.
- Ueno, S., et al., "Ultrasound Thermometry in Hyperthermia", 1990 *Ultrasonic Symposium*, pp. 1645-1652.
- Verhofstad, Michiel H.J. et al., "Collagen Synthesis in rat skin and ileum fibroblasts is affected differently by diabetes-related factors" *Int. J. Exp. Path.* (1998), 79, 321-328.
- Wang, H., et al., "Limits on Focused Ultrasound for Deep Hyperthermia", 1994 *Ultrasonic Symposium*, Nov. 1-4, 1994, pp. 1869-1872, vol. 3.
- Wasson, Scott, "NVIDIA's GeForce 7800 GTX graphics processor Power MADD," <http://techreport.com/reviews/2005q2/geforce-7800gtx/index.x?pg=1>, Jun. 22, 2005, 4 pages.
- Weiss, M., "Commentary: noninvasive skin tightening: ultrasound and other technologies: where are we in 2011?" *Dermatol Surg*, 2012. 38(1): p. 28-30.
- White et al "Selective Creating of Thermal Injury Zones in the Superficial Musculoaponeurotic System Using Intense Ultrasound Therapy," *Arch Facial Plastic Surgery*, Jan./Feb. 2007, vol. 9, No. 1 (pp. 22-29).
- White, W. M., et al., "Selective Transcutaneous Delivery of Energy to Facial Subdermal Tissues Using the Ultrasound Therapy System" [abstr]. *American Society for Laser Medicine and Surgery Abstracts*, p. 37 #113 (Apr. 2006).
- White, W. Matthew, et al., "Selective Transcutaneous Delivery of Energy to Porcine Soft Tissues Using Intense Ultrasound (IUS)" *Lasers in Surgery and Medicine* 40:67-75 (2008).
- Woodward, J.A., et al. "Safety and Efficacy of Combining Microfocused Ultrasound With Fractional CO2 Laser Resurfacing for Lifting and Tightening the Face and Neck". *Dermatol Surg*, Dec. 2014 40:S190-S193.
- Zelickson, Brian D. et al., "Histological and Ultrastructural Evaluation of the Effects of a Radiofrequency-Based Nonablative Dermal Remodeling Device, A Pilot Study" *Arch Dermatol*, vol. 140, (Feb. 2004).
- Ulthera, Inc., Petition for Inter Partes Review filed Jul. 19, 2016 in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 63 pages (Filed Jul. 19, 2016).
- Ulthera Exhibit 1001, U.S. Pat. No. 6,113,559 to Klopotek, filed Jul. 19, 2016 in re IPR2016-01459.
- Ulthera Exhibit 1002, Patent file history of U.S. Pat. No. 6,113,559 Klopotek filed Jul. 19, 2016 in re IPR2016-01459.
- Ulthera Exhibit 1003, Declaration of Expert Witness Mark E. Schafer, Ph.D. filed Jul. 19, 2016 in re IPR2016-01459.
- Ulthera Exhibit 1004, Curriculum Vitae of Mark E. Schafer, Ph.D. filed Jul. 19, 2016 in re IPR2016-01459.
- Ulthera Exhibit 1005, International PCT Publication WO96/34568 Knowlton filed Jul. 19, 2016 in re IPR2016-01459.
- Ulthera Exhibit 1006, French U.S. Pat. No. 2,672,486, Technomed patent filed Jul. 19, 2016 in re IPR2016-01459.
- Ulthera Exhibit 1007, English translation of French U.S. Pat. No. 2,672,486, Technomed filed Jul. 19, 2016 in re IPR2016-01459.
- Ulthera Exhibit 1008, International PCT Publication WO93/12742, Technomed PCT filed Jul. 19, 2016 in re IPR2016-01459.
- Ulthera Exhibit 1009, English translation of International PCT Publication WO93/12742, Technomed PCT filed Jul. 19, 2016 in re IPR2016-01459.
- Ulthera Exhibit 1010, U.S. Pat. No. 5,601,526, which claims priority to Technomed PCT filed Jul. 19, 2016 in re IPR2016-01459.
- Ulthera Exhibit 1011, Patent file history for European Patent Application No. 98964890.2, Klopotek filed Jul. 19, 2016 in re IPR2016-01459.
- Ulthera Exhibit 1012, Translator Declaration filed Jul. 19, 2016 in re IPR2016-01459.
- Ulthera Exhibit 1013, U.S. Pat. No. 5,230,334 to Klopotek filed Jul. 19, 2016 in re IPR2016-01459.
- Ulthera Exhibit 1014, U.S. Pat. No. 5,755,753 to Knowlton filed Jul. 19, 2016 in re IPR2016-01459.
- Ulthera Exhibit 1015, Excerpts from *The American Medical Association Encyclopedia of Medicine (1989)* filed Jul. 19, 2016 in re IPR2016-01459.
- Ulthera Exhibit 1016, *The Simultaneous Study of Light Emissions and Shock Waves Produced by Cavitation Bubbles*, G. Gimenez, *J. Acoust. Soc. Am.* 71(4), Apr. 1982, pp. 839-847 (filed Jul. 19, 2016 in re IPR2016-01459).
- Ulthera Exhibit 1017, Excerpts from *Gray's Anatomy (1995)* (filed Jul. 19, 2016 in re IPR2016-01459).
- Ulthera Exhibit 1018, *Anatomy of the Superficial Venous System*, Comjen G.M., *Dermatol. Surg.*, 1995; 21:35-45 (filed Jul. 19, 2016 in re IPR2016-01459).
- Ulthera Exhibit 1019, Section 2.6 from *Ultrasonics Theory and Application*, by G.L. Gooberman (Hart Publishing Co., 1969) (filed Jul. 19, 2016 in re IPR2016-01459).
- Ulthera Exhibit 1020, *Deep Local Hyperthermia for Cancer Therapy: External Electromagnetic and Ultrasound Techniques*, A.Y. Cheung and A. Neyzari, *Cancer Research (Suppl.)*, vol. 44, pp. 4736-4744 (1984) (filed Jul. 19, 2016 in re IPR2016-01459).

* cited by examiner




FIG. 1




FIG. 2




FIG. 3A




FIG. 3B




FIG. 4A




FIG. 4B




FIG. 5




FIG. 6A




FIG. 6B




FIG. 7




FIG. 8A




FIG. 8B




FIG. 9




FIG. 10A




FIG. 10B




FIG. 10C




FIG. 10D




FIG. 10E




FIG. 10F




FIG. 11




FIG. 12




FIG. 13




FIG. 14A




FIG. 14B




FIG. 15




FIG. 16A




FIG. 16B




FIG. 17




FIG. 18A




FIG. 18B

ENERGY BASED FAT REDUCTION

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 15/041,804, filed Feb. 11, 2016, now U.S. Pat. No. 9,533,175, which is a continuation of U.S. application Ser. No. 14/550,772, filed Nov. 21, 2014, now U.S. Pat. No. 9,283,409, which is a continuation of U.S. application Ser. No. 14/192,520 filed Feb. 27, 2014, now U.S. Pat. No. 8,920,324, which is a continuation of U.S. application Ser. No. 12/646,609 filed Dec. 23, 2009, now U.S. Pat. No. 8,663,112, which is a continuation-in-part of U.S. application Ser. No. 11/163,154 filed on Oct. 6, 2005, now U.S. Pat. No. 8,133,180, which claims the benefit of priority to U.S. Provisional No. 60/616,753 filed on Oct. 6, 2004, each of which are hereby incorporated by reference in their entirety herein. In addition, U.S. application Ser. No. 12/646,609, now U.S. Pat. No. 8,663,112, claims the benefit of priority from U.S. Provisional No. 61/140,725 filed on Dec. 24, 2008, which is hereby incorporated by reference in its entirety herein. Any and all priority claims identified in the Application Data Sheet, or any correction thereto, are hereby incorporated by reference under 37 CFR 1.57.

BACKGROUND

Field of the Invention

The present invention relates to ultrasound therapy systems, and in particular to methods and systems for treating cellulite or reducing fat.

Description of the Related Art

In general, cellulite refers to a common skin disorder which is characterized by a dimple appearance in a person's skin that may be found on the hips, thighs, and/or buttocks. Underneath the dermis and epidermis layers of the skin there are multiple layers of fat. Cellulite tends to develop in the subcutaneous fat layers, which is unique as compared to other fat layers because the subcutaneous fat can be structured into specific chambers surrounded by strands of linked tissue, which are known as fat lobuli. This appearance is much more common in women than in men because of differences in the way fat, muscle, and connective tissue are distributed in men's and women's skin. The lumpiness of cellulite is caused by the fat lobuli that push and distort the connective tissues beneath the skin; resulting protrusions and depressions of connective tissue anchor points create the appearance of cellulite.

Invasive treatments for cellulite include Iontophoresis, liposuction, and electrolipophoresis, which can involve an application of a low-frequency electric current. Non-invasive treatments for cellulite can include laser and suction massage combination therapy, pneumatic pressure massage therapy, lymphatic drainage massage, and low-frequency ultrasound diathermy. Such invasive and non-invasive treatments have yielded marginal results. In addition, a number of drugs that act on fatty tissue have been tried as therapeutic agents for cellulite treatment. Such drugs can be administered orally, applied topically as ointments, or by transdermal injection. At this point, no drug has been reported in the scientific literature as having a significant effect on cellulite. New developments for the treatment of cellulite are needed.

In addition, similar techniques have attempted to address the reduction of fat in humans, but such attempts have likewise had mixed results.

SUMMARY

In accordance with various aspects of the present invention, non-invasive methods and systems for fat reduction and/or treatment of cellulite are provided. In accordance with an exemplary embodiment, a non-invasive method for cellulite treatment can include targeting a region of interest below a surface of skin, which contains fat lobuli and delivering ultrasound energy to the region of interest. The ultrasound energy generates a conformal lesion with said ultrasound energy on a surface of a fat lobuli. The lesion creates an opening in the surface of the fat lobuli, which allows the draining of a fluid out of the fat lobuli and through the opening.

In accordance with an exemplary embodiment, a non-invasive method for cellulite treatment can include targeting fat cells in a subcutaneous fat layer and delivering ultrasound energy to raise the temperature of the fat cells, stimulating apoptosis of the fat cells and then allowing the targeted fat cells to die, thereby reducing a quantity of fat cells in the subcutaneous layer.

Further areas of applicability will become apparent from the description provided herein. It should be understood that the description and specific examples are intended for purposes of illustration only and are not intended to limit the scope of the present invention.

BRIEF DESCRIPTION OF THE DRAWINGS

The drawings described herein are for illustration purposes only and are not intended to limit the scope of the present disclosure in any way. The present invention will become more fully understood from the detailed description and the accompanying drawings wherein:

FIG. 1 illustrates a block diagram of an ultrasound treatment system for treating cellulite in accordance with exemplary embodiments of the present invention;

FIG. 2 illustrates a cross-sectional diagram of a transducer system in accordance with exemplary embodiments of the present invention;

FIGS. 3A and 3B illustrate block diagrams of an exemplary control system in accordance with exemplary embodiments of the present invention;

FIGS. 4A and 4B illustrate block diagrams of an exemplary probe system in accordance with exemplary embodiments of the present invention;

FIG. 5 illustrates a cross-sectional diagram of an exemplary transducer in accordance with exemplary embodiments of the present invention;

FIGS. 6A and 6B illustrate cross-sectional diagrams of an exemplary transducer in accordance with exemplary embodiments of the present invention;

FIG. 7 illustrates exemplary transducer configurations for ultrasound treatment in accordance with exemplary embodiments of the present invention;

FIGS. 8A and 8B illustrate cross-sectional diagrams of an exemplary transducer in accordance with exemplary embodiments of the present invention;

FIG. 9 illustrates an exemplary transducer configured as a two-dimensional array for ultrasound treatment in accordance with exemplary embodiments of the present invention;

FIGS. 10A-10F illustrate cross-sectional diagrams of exemplary transducers in accordance with exemplary embodiments of the present invention;

FIG. 11 illustrates a schematic diagram of an acoustic coupling and cooling system in accordance with exemplary embodiments of the present invention;

FIG. 12 illustrates a block diagram of a treatment system comprising an ultrasound treatment subsystem combined with additional subsystems and methods of treatment monitoring and/or treatment imaging as well as a secondary treatment subsystem in accordance with exemplary embodiments of the present invention;

FIG. 13 is a cross-sectional diagram illustrating a method of treating cellulite in accordance with exemplary embodiments of the present invention;

FIGS. 14A and 14B are cross-sectional diagrams illustrating another method of treating cellulite in accordance with exemplary embodiments of the present invention;

FIG. 15 is a block diagram illustrating a method of treating cellulite in accordance with exemplary embodiments of the present invention;

FIGS. 16A and 16B are cross-sectional diagrams illustrating a method of reducing fat and treating cellulite in accordance with exemplary embodiments of the present invention;

FIG. 17 is a block diagram illustrating a method of fat reduction in accordance with exemplary embodiments of the present invention; and

FIGS. 18A and 18B are cross-sectional diagrams illustrating a method of reducing fat in accordance with exemplary embodiments of the present invention.

DETAILED DESCRIPTION

The following description is merely exemplary in nature and is not intended to limit the present invention or its teachings, applications, or uses thereof. It should be understood that throughout the drawings, corresponding reference numerals indicate like or corresponding parts and features. The description of specific examples indicated in various embodiments and aspects of the present invention are intended for purposes of illustration only and are not intended to limit the scope of the invention disclosed herein. Moreover, recitation of multiple embodiments having stated features is not intended to exclude other embodiments having additional features or other embodiments incorporating different combinations of the stated features.

The present invention may be described herein in terms of various functional components and processing steps. It should be appreciated that such components and steps may be realized by any number of hardware components configured to perform the specified functions. For example, the present invention may employ various medical treatment devices, visual imaging and display devices, input terminals and the like, which may carry out a variety of functions under the control of one or more control systems or other control devices. In addition, the present invention may be practiced in any number of medical or cosmetic contexts and the exemplary embodiments relating to a non-invasive methods and systems for fat reduction and/or cellulite treatment as described herein are merely indicative of exemplary applications for the invention. For example, various of the principles, features and methods discussed herein may be applied to any medical or cosmetic application, or other related applications.

Various aspects of the present invention provide a method of non-invasive treatment of cellulite. The method includes

targeting a region of interest below a surface of skin, which contains fat lobuli and delivering ultrasound energy to the region of interest. The ultrasound energy generates a conformal lesion within the ultrasound energy on a surface of a fat lobuli, such as, for example, by creating a sharp focal of ultrasound energy onto the fat lobuli. The lesion creates an opening in the surface of the fat lobuli, such as, for example, by piercing the fat lobuli, which allows the draining of a fluid out of the fat lobuli through the opening.

Various aspects of the present invention can also provide a method for fat reduction that can include heating a region of interest to a temperature in a range from about 43° C. to about 49° C., which can stimulate apoptosis of at least one fat cell in the fat lobuli. Still further, the method can include applying a physical treatment to said surface of skin and such physical treatment can include mesotherapy, iontophoresis, pressotherapy, pneumatic massage, lymphatic drainage, electrolipophoresis, roller massage, low frequency ultrasound, vacuum suction, laser energy, and application of RF energy. The physical treatment can be before, after, or concurrent with the delivery of the ultrasound energy. The method can include the use of a second energy, which can be used before, after, or concurrent with the delivery of the ultrasound energy. The method can reduce the appearance of cellulite on the surface of skin.

Various aspects of the present invention provide a method of non-invasively stimulating apoptosis of a fat cell located in a subcutaneous fat layer. The method include targeting at least one fat cell in a subcutaneous layer below a skin surface and delivering energy to the fat cell. The delivered energy raises a temperature of the fat cell into a range from about 43° C. to about 49° C., which stimulates apoptosis of the fat cell.

The method can further include imaging of the fat cell. Still further, the method can include generating a conformal lesion into said at least one fat cell, which can create an opening in the fat cell and allow the moving of a material out of the fat cell through the opening. The energy is typically ultrasound energy in the range of about 750 kHz to about 20 MHz or in a range from about 2 MHz to about 20 MHz, or other more specific ranges. Still further the method can include applying a physical treatment to said surface of skin and such physical treatment can include mesotherapy, iontophoresis, pressotherapy, pneumatic massage, lymphatic drainage, electrolipophoresis, roller massage, low-frequency ultrasound, vacuum suction, laser energy, and application of RF energy. The physical treatment can be before, after, or concurrent with the delivery of the energy. The method can include the use of a second energy, which can be used before, after, or concurrent with the delivery of the energy. The method can reduce the number of fat cells in the subcutaneous fat layer.

In addition, various aspects of the present invention provide a method that combines fat reduction and cellulite reduction. The method includes targeting a region of interest below a surface of skin, which contains fat lobuli, and delivering ultrasound energy to the region of interest. The ultrasound energy generates a conformal lesion with said ultrasound energy on a surface of a fat lobuli. The lesion creates an opening in the surface of the fat lobuli, which allows the draining of a fluid out of the fat lobuli through the opening. Additionally, the method can include targeting at least one fat cell in a subcutaneous layer below a skin surface and delivering a second energy to the fat cell. The delivered second energy raises a temperature of the fat cell into a range from about 43° C. to about 49° C., which stimulates apoptosis of the fat cell.

The method can further include a physical treatment as described herein, as well as the use of a secondary energy source. The method can both reduce the number of fat cells in the subcutaneous fat layer and reduce the appearance of cellulite on a skin surface. The method can be effective in physically breaking fat cell clusters and stretching fibrous bonds of cellulite.

In accordance with an exemplary embodiment, a method of non-invasive treatment of cellulite can include targeting a region of interest below a skin surface, which contains fat lobuli, and delivering ultrasound energy at a specified depth below the skin surface. The method further includes moving a source of the energy along the skin surface and ablating a portion of the fat lobuli at the specified depth below the skin surface.

In accordance with the exemplary method, a specified depth is generally in the range of about 1 mm to about 35 mm below the skin surface. The method can include applying a physical treatment as described herein. The method can smooth the skin surface and may reduce the appearance of cellulite on the skin surface. The method can further include any of the additional method steps discussed herein.

In accordance with various aspects of the present invention, non-invasive methods and systems for the reduction of fat and/or the treating of cellulite are provided. For example, in accordance with an exemplary embodiment, with reference to FIG. 1, an exemplary treatment system **100** configured to treat a region of interest **106** comprises a control system **102**, an imaging/therapy probe with acoustic coupling **104**, and a display system **108**.

Control system **102** and display system **108** can comprise various configurations for controlling probe **104** and overall system **100** functionality. In various embodiments, control system **102** can include, for example but not limited to any of the following, a microprocessor with software and a plurality of input/output devices, systems or devices for controlling electronic and/or mechanical scanning and/or multiplexing of transducers, systems for power delivery, systems for monitoring, systems for sensing the spatial position of the probe and/or transducers, and/or systems for handling user input and recording treatment results, among others. Imaging/therapy probe **104** can comprise various probe and/or transducer configurations. For example, probe **104** can be configured for a combined dual-mode imaging/therapy transducer, coupled or co-housed imaging/therapy transducers, or simply a separate therapy probe and an imaging probe.

In accordance with an exemplary embodiment, treatment system **100** is configured for treating a deep tissue region that contains a lower part of dermis and proximal protrusions of fat lobuli into the dermis by, first, imaging region of interest (“ROI”) **210** for localization of the treatment area and surrounding structures, second, delivering ultrasound energy at a depth, distribution, timing, and energy level to achieve the desired therapeutic effect, and third monitoring the treatment area before, during, and after therapy to plan and assess the results and/or provide feedback. As to the delivery of energy, control system **102** and transducer system **102** can be suitably configured to deliver conformal ultrasound therapeutic energy to ROI **210** creating a thermal injury and coagulating the proximal protrusions of fat lobuli, thereby eliminating the fat protrusions into the dermis. As used herein, the term “dermis” refers to any part of the dermis and/or the epidermis.

Because the location and thickness of the fat lobuli varies from one patient to another (due to genetics, weight, age,

etc.), imaging using a transducer can facilitate treatment within a patient, however imaging is not required to treat cellulite.

By planning a treatment protocol, the user may choose one or more spatial and/or temporal characteristics to provide conformal ultrasound energy to ROI **210**. For example, the user may select one or more spatial characteristics to control, including, for example, the use of one or more transducers, one or more mechanical and/or electronic focusing mechanisms, one or more transduction elements, one or more placement locations of the transducer relative to ROI **210**, one or more feedback systems, one or more mechanical arms, one or more orientations of the transducer, one or more temperatures of treatment, one or more coupling mechanisms and/or the like.

In addition, the user may choose one or more temporal characteristics to control in order to facilitate treatment of ROI **210**. For example, the user may select and/or vary the treatment time, frequency, power, energy, amplitude and/or the like in order to facilitate temporal control. For more information on selecting and controlling ultrasound spatial and temporal characteristics, see U.S. application Ser. No. 11/163,148, entitled “Method and System for Controlled Thermal Injury”, filed Oct. 6, 2005, published on Jun. 1, 2006 as U.S. Patent Application Publication No. 20060116671, and incorporated herein by reference.

After planning of a treatment protocol is complete, the treatment protocol can be implemented. That is, a transducer system can be used to deliver ultrasound energy to a treatment region to ablate select tissue in order to facilitate cellulite treatment. By delivering energy, the transducer may be driven at a select frequency, a phased array may be driven with certain temporal and/or spatial distributions, a transducer may be configured with one or more transduction elements to provide focused, defocused and/or planar energy, and/or the transducer may be configured and/or driven in any other ways hereinafter devised.

For treatment of ROI **210**, transducer system **102** may be configured to deliver one or more energy fields to promote one or more effects, for example, ablation of existing tissue, the breaking up of fat cell clusters, stretching of the fibrous bonds, enhancement of lymphatic drainage, stimulation of the evacuation of fat decay products, and/or enhanced cell permeability in order to treat cellulite. Additionally, for treatment of ROI **210**, transducer system **102** may be configured to deliver one or more energy fields to promote one or more effects, for example cell apoptosis, piercing cells to promote drainage, and ablating a layer of fat cells to a specified distance below a skin surface, such as for example giving the fat cells a haircut. Of course transducer system may be configured to deliver one energy field as needed by any of the methods of treatment described herein. As described herein, imaging is not necessary for treatment methods or treatment plans but rather is an optional step. For example, the dimpled pattern of cellulite is typically visible on the surface of a patient’s skin and the system user can easily identify ROI **210** that will be treated.

Through operation of treatment system **100**, a method for treatment of cellulite can be realized that can facilitate effective and efficient therapy without creating chronic injury to human tissue. For example, a user may first select one or more transducer probe configurations for treating ROI **210**. The user may select any probe configuration described herein. Because the treatment region ranges from about 0 mm to greater than about 5.5 cm or from about 1 mm to about 3.5 cm, exemplary transducer probes may include, for example, an annular array, a variable depth transducer, a

mechanically moveable transducer, a cylindrical-shaped transducer, a linear or flat transducer and the like. As used herein, the term user may include a person, employee, doctor, nurse, and/or technician, utilizing any hardware and/or software of other control systems.

Once one or more transducers are selected, the user may then image ROI 210 in order to plan a treatment protocol. By imaging ROI 210, the user may use the same treatment transducer probe and/or one or more additional transducers to image ROI 210 at a high resolution. In one embodiment, the transducer may be configured to facilitate high speed imaging over a large ROI 210 to enable accurate imaging over a large ROI 210. In another embodiment, ultrasound imaging may include, individually or in combination, the use of Doppler flow monitoring and/or color flow monitoring. In addition, other means of imaging such as photography and other visual optical methods, MRI, X-Ray, PET, infrared or others can be utilized separately or in combination for imaging and feedback of the superficial tissue and the vascular tissue in ROI 210.

An exemplary ultrasound therapy system of FIG. 1 is further illustrated in an exemplary embodiment in FIG. 2. A therapy transducer system 200 includes a transducer probe 202 connected to control system 204, and display 206, in combination may provide therapy, imaging, and/or temperature or other tissue parameters monitoring to ROI 210. Exemplary transducer system 200 is configured for, first, imaging and display of ROI 210 for localization of the treatment area and surrounding structures, second, delivery of focused, unfocused, or defocused ultrasound energy at a depth, distribution, timing, and energy level to achieve the desired therapeutic effect of thermal ablation to treat cellulite, and, third, to monitor the treatment area and surrounding structures before, during, and after therapy to plan and assess the results and/or provide feedback to control system 204 and/or an operator.

Exemplary transducer probe 202 can be configured to be suitably controlled and/or operated in various manners. For example, transducer probe 202 may be configured for use within an ultrasound treatment system, an ultrasound imaging system and/or an ultrasound imaging, therapy, and/or treatment monitoring system, including motion control subsystems.

Control system 204 can be configured with one or more subsystems, processors, input devices, displays and/or the like. Display 206 may be configured to image and/or monitor ROI 210 and/or any particular sub-region within ROI 210. Display 206 can be configured for two-dimensional, three-dimensional, real-time, analog, digital and/or any other type of imaging. Exemplary embodiments of both control system 204 and display 206 are described in greater detail herein.

ROI 210, can be comprised of superficial layer (epidermis/dermis) subcutaneous fat, lobuli, and muscle. Exemplary transducer system 200 is configured to provide cross-sectional two-dimensional imaging of the region 207, displayed as an image 205, with a controlled thermal lesion 209, confined approximately to proximal portion of fat lobuli and lower portion of dermis.

Transducer system 200 can be configured with the ability to controllably produce conformal treatment areas in superficial human tissue within ROI 210 through precise spatial and temporal control of acoustic energy deposition. In accordance with an exemplary embodiment, control system 204 and transducer probe 202 can be suitably configured for spatial control of the acoustic energy by controlling the manner of distribution of the acoustical energy. For

example, spatial control may be realized through selection of the type of one or more transducer configurations insonifying ROI 210, selection of the placement and location of transducer probe 202 for delivery of acoustical energy relative to ROI 210, e.g., transducer probe 202 configured for scanning over part or whole of ROI 210 to deliver conformal ultrasound therapeutic energy to create a thermal injury, such as a lesion, and to coagulate the proximal protrusions of fat lobuli, thereby eliminating the fat protrusions into the dermis. Transducer probe 202 may also be configured for control of other environment parameters, e.g., the temperature at the acoustic coupling interface can be controlled. In addition to the spatial control, control system 204 and/or transducer probe 202 can also be configured for temporal control, such as through adjustment and optimization of drive amplitude levels, frequency/waveform selections, and timing sequences and other energy drive characteristics to control the treatment of tissue. The spatial and/or temporal control can also be facilitated through open-loop and closed-loop feedback arrangements, such as through the monitoring of various positional and temporal characteristics. For example, through such spatial and/or temporal control, an exemplary treatment system 200 can enable the regions of thermal injury to possess arbitrary shape and size and allow the tissue to be treated in a controlled manner.

Transducer system 200 may be used to provide a mechanical action of ultrasound to physically break fat cell clusters and stretch the fibrous bonds. This mechanical action will also enhance lymphatic drainage, stimulating the evacuation of fat decay products. That is, the ultrasound may facilitate movement of the muscles and soft tissues within ROI 210, thereby facilitating the loosening of fat deposits and/or the break up of fibrous tissue surrounding fat deposits.

In addition, transducer system 200 can be configured to deliver various therapeutic levels of ultrasound to increase the speed at which fat metabolizes, according to Arrhenius' Law: $K=Ae^{sup.-B/T}$, where K is the kinetic rate of fat metabolism, A is a constant, B is the activation energy, and T is the temperature in degrees Kelvin. According to Arrhenius' Law, a metabolic reaction is a function of temperature. In exemplary embodiments, transducer system 200 is configured to provide various therapeutic levels of ultrasound to increase a temperature of fat cells in order to maximize the speed at which fat metabolizes. Moreover, transducer system 200 can be configured to deliver various therapeutic levels of ultrasound to increase the speed at which fat metabolizes. According to a modified equation of Arrhenius' Law, a metabolic reaction is a function of temperature and time, $T: K=Ate^{sup.-B/T}$, where K is the kinetic rate of fat metabolism, A is a constant, B is the activation energy, t is time, and T is the temperature in degrees Kelvin. In exemplary embodiments, transducer system 200 is configured to provide various therapeutic levels of ultrasound for a specified time period or for a pulsed delivery over time to increase a temperature of fat cells in order to maximize the speed at which fat metabolizes. Moreover, transducer system 200 can be configured to deliver various therapeutic levels of ultrasound for a specified time period or for a pulsed delivery over time to increase the speed at which fat metabolizes. Thus, ultrasound treatment from transducer system 200, ranging from approximately 750 kHz to 20 MHz, can increase the temperature in a treatment area, thereby increasing the metabolic reaction yield for that treatment area. As such, fat metabolism in the treatment area is increased which leads to fat cell reduction and decreases the appearance of cellulite above the treat-

ment area. Ultrasound treatment from transducer **200** can be programmed to provide appropriate temperatures and optionally for appropriate time to ROI **210** to increase the spread of fat cell metabolism leading to fat cell destruction and optionally reducing the appearance of cellulite.

In some aspects of the present invention, a method of increasing metabolism of fat cells in a subcutaneous fat layer is provided. The method can include targeting a plurality of fat cells in a subcutaneous fat layer, heating the plurality of fat cells to a temperature as defined by Arrhenius' Law, increasing a metabolism of at least a portion of the plurality of fat cells, and reducing a portion of the plurality of fat cells. The method can also include any physical treatment described herein before, after, and/or concurrent with increasing the metabolism of the fat cells. In addition, the method can include the use a secondary energy as described herein.

As previously described, control systems **104** and **204** may be configured in a variety of manners with various subsystems and subcomponents. With reference to FIGS. **3A** and **3B**, in accordance with exemplary embodiments, an exemplary control system **300** can be configured for coordination and control of the entire therapeutic treatment process in accordance with the adjustable settings made by a therapeutic treatment system user. For example, control system **300** can suitably comprise power source components **302**, sensing and monitoring components **304**, cooling and coupling controls **306**, and/or processing and control logic components **308**. Control system **300** can be configured and optimized in a variety of ways with more or less subsystems and components to implement the therapeutic system for cellulite treatment, and the embodiment in FIGS. **3A** and **3B** are merely for illustration purposes.

For example, for power sourcing components **302**, control system **300** can comprise one or more direct current (DC) power supplies **303** configured to provide electrical energy for entire control system **300**, including power required by transducer electronic amplifier/driver **312**. DC current sense device **305** can also be provided to confirm the level of power going into amplifiers/drivers **312** for safety and monitoring purposes.

Amplifiers/drivers **312** can comprise multi-channel or single channel power amplifiers and/or drivers. In accordance with an exemplary embodiment for transducer array configurations, amplifiers/drivers **312** can also be configured with a beamformer to facilitate array focusing. An exemplary beamformer can be electrically excited by an oscillator/digitally controlled waveform synthesizer **310** with related switching logic.

Power sourcing components **302** can also include various filtering configurations **314**. For example, switchable harmonic filters and/or matching may be used at the output of amplifier/driver **312** to increase the drive efficiency and effectiveness. Power detection components **316** may also be included to confirm appropriate operation and calibration. For example, electric power and other energy detection components **316** may be used to monitor the amount of power going to an exemplary probe system.

Various sensing and monitoring components **304** may also be suitably implemented within control system **300**. For example, in accordance with an exemplary embodiment, monitoring, sensing and interface control components **324** may be configured to operate with various motion detection systems implemented within transducer probe **104** to receive and process information such as acoustic or other spatial and temporal information from ROI **210**. Sensing and monitoring components can also include various controls, interfac-

ing and switches **309** and/or power detectors **316**. Such sensing and monitoring components **304** can facilitate open-loop and/or closed-loop feedback systems within treatment system **100**.

For example, in such an open-loop system, a system user can suitably monitor the imaging and/or other spatial or temporal parameters and then adjust or modify the same to accomplish a particular treatment objective. Instead of, or in combination with, open-loop feedback configurations, an exemplary treatment system can comprise a closed-loop feedback system, wherein images and/or spatial/temporal parameters can be suitably monitored within monitoring components **304** to generate signals.

During operation of exemplary treatment system **100**, a lesion configuration of a selected size, shape, and orientation is determined. Based on that lesion configuration, one or more spatial parameters are selected, along with suitable temporal parameters, the combination of which yields the desired conformal lesion. Operation of the transducer can then be initiated to provide the conformal lesion or lesions. Open and/or closed-loop feedback systems can also be implemented to monitor the spatial and/or temporal characteristics, and/or other tissue parameter monitoring, to further control the conformal lesions.

Cooling/coupling control systems **306** may be provided to remove waste heat from exemplary probe **104**, provide a controlled temperature at the superficial tissue interface and deeper into tissue, and/or provide acoustic coupling from transducer probe **104** to ROI **210**. Such cooling/coupling control systems **306** can also be configured to operate in both open-loop and/or closed-loop feedback arrangements with various coupling and feedback components.

Processing and control logic components **308** can comprise various system processors and digital control logic **307**, such as one or more of microcontrollers, microprocessors, field-programmable gate arrays (FPGAs), computer boards, and associated components, including firmware and control software **326**, which interfaces to user controls and interfacing circuits as well as input/output circuits and systems for communications, displays, interfacing, storage, documentation, and other useful functions. System software and firmware **326** controls all initialization, timing, level setting, monitoring, safety monitoring, and all other system functions required to accomplish user-defined treatment objectives. Further, various control switches **308** can also be suitably configured to control operation.

An exemplary transducer probe **104** can also be configured in various manners and can comprise a number of reusable and/or disposable components and parts in various embodiments to facilitate its operation. For example, transducer probe **104** can be configured within any type of transducer probe housing or arrangement for facilitating the coupling of a transducer to a tissue interface, with such housing comprising various shapes, contours and configurations depending on the particular treatment application. For example, in accordance with an exemplary embodiment, transducer probe **104** can be depressed against a tissue interface whereby blood perfusion is partially or wholly cut-off, and tissue is flattened in superficial treatment ROI **210**. Transducer probe **104** can comprise any type of matching, such as for example, electric matching, which may be electrically switchable; multiplexer circuits and/or aperture/element selection circuits; and/or probe identification devices, to certify probe handle, electric matching, transducer usage history and calibration, such as one or more serial EEPROM (memories).

Transducer probe **104** may also comprise cables and connectors; motion mechanisms, motion sensors and encoders; thermal monitoring sensors; and/or user control and status related switches, and indicators such as LEDs. For example, a motion mechanism in probe **104** may be used to controllably create multiple lesions, or sensing of probe motion itself may be used to controllably create multiple lesions and/or stop creation of lesions, e.g. for safety reasons if probe **104** is suddenly jerked or is dropped. In addition, an external motion encoder arm may be used to hold the probe during use, whereby the spatial position and attitude of probe **104** is sent to the control system to help controllably create lesions. Furthermore, other sensing functionality such as profilometers or other imaging modalities may be integrated into the probe in accordance with various exemplary embodiments.

With reference to FIGS. **4A** and **4B**, in accordance with an exemplary embodiment, transducer probe **400** can comprise control interface **402**, transducer **404**, coupling components **406**, and monitoring/sensing components **408**, and/or motion mechanism **410**. However, transducer probe **400** can be configured and optimized in a variety of ways with more or less parts and components to provide ultrasound energy for cellulite treatment and/or fat reduction, and the embodiments illustrated in FIGS. **4A** and **4B** are merely for illustration purposes. In some embodiments, transducer probe **104** is equivalent to transducer probe **400**. In some embodiments, transducer probe **104**, discussed above, can comprise control interface **402**, transducer **404**, coupling components **406**, and monitoring/sensing components **408**, and/or motion mechanism **410**.

In accordance with an exemplary embodiment of the present invention, transducer probe **400** is configured to deliver energy over varying temporal and/or spatial distributions in order to provide energy effects and initiate responses in ROI **210**. These effects can include, for example, thermal, cavitation, hydrodynamic, and resonance induced tissue effects. For example, exemplary transducer probe **400** can be operated under one or more frequency ranges to provide two or more energy effects and initiate one or more responses in ROI **210**. In addition, transducer probe **400** can also be configured to deliver planar, defocused and/or focused energy to ROI **210** to provide two or more energy effects and to initiate one or more reactions. These responses can include, for example, diathermy, hemostasis, revascularization, angiogenesis, growth of interconnective tissue, tissue reformation, ablation of existing tissue, protein synthesis, cell apoptosis, and/or enhanced cell permeability.

These and various other exemplary embodiments of systems and components for such combined ultrasound treatment, effects and responses are more fully set forth in U.S. patent application Ser. No. 10/950,112, entitled "Method and System for Combined Ultrasound Treatment", filed Sep. 24, 2004, published on Apr. 6, 2006 as U.S. Patent Application Publication No. 20060074355, and incorporated herein by reference.

In addition, these and various other exemplary embodiments of systems and components for such combined ultrasound treatment, effects and responses are more fully set forth in U.S. Pat. No. 6,050,943, entitled "Imaging, Therapy, and Temperature Monitoring Ultrasonic System", issued Apr. 18, 2000, and U.S. Pat. No. 6,500,121 entitled "Imaging, Therapy, and temperature Monitoring Ultrasonic System," issued Dec. 31, 2002, both of which are incorporated herein by reference.

Control interface **402** is configured for interfacing with control system **300** to facilitate control of transducer probe **400**. Control interface components **402** can comprise multiplexer/aperture select **424**, switchable electric matching networks **426**, serial EEPROMs and/or other processing components and matching and probe usage information **430** and interface connectors **432**.

Coupling components **406** can comprise various devices to facilitate coupling of transducer probe **400** to ROI **210**. For example, coupling components **406** can comprise cooling and acoustic coupling system **420** configured for acoustic coupling of ultrasound energy and signals. Coupling system **420** with possible connections such as manifolds may be utilized to couple sound into ROI **210**, control temperature at the interface and deeper into tissue, provide liquid-filled lens focusing, and/or to remove transducer waste heat. Coupling system **420** may facilitate such coupling through use of various coupling mediums, including air and other gases, water and other fluids, gels, solids, and/or any combination thereof, or any other medium that allows for signals to be transmitted between transducer active elements **412** and ROI **210**. In addition to providing a coupling function, in accordance with an exemplary embodiment, coupling system **420** can also be configured for providing temperature control during the treatment application. For example, coupling system **420** can be configured for controlled cooling of an interface surface or region between transducer probe **400** and ROI **210** and beyond by suitably controlling the temperature of the coupling medium. The suitable temperature for such coupling medium can be achieved in various manners, and utilize various feedback systems, such as thermocouples, thermistors or any other device or system configured for temperature measurement of a coupling medium. Such controlled cooling can be configured to further facilitate spatial and/or thermal energy control of transducer probe **400**.

Monitoring and sensing components **408** can comprise various motion and/or position sensors **416**, temperature monitoring sensors **418**, user control and feedback switches **414** and other like components for facilitating control by control system **300**, e.g., to facilitate spatial and/or temporal control through open-loop and closed-loop feedback arrangements that monitor various spatial and temporal characteristics.

Motion mechanism **410** can comprise manual operation, mechanical arrangements, or some combination thereof. For example, motion mechanism **422** can be suitably controlled by control system **300**, such as through the use of accelerometers, encoders or other position/orientation devices **416** to determine and enable movement and positions of transducer probe **400**. Linear, rotational or variable movement can be facilitated, e.g., those depending on the treatment application and tissue contour surface.

Transducer **404** can comprise one or more transducers configured for producing conformal lesions of thermal injury in superficial human tissue within ROI **210** through precise spatial and temporal control of acoustic energy deposition. Transducer **404** can also comprise one or more transduction elements and/or lenses **412**. The transduction elements can comprise a piezoelectrically active material, such as lead zirconate titanate (PZT), or any other piezoelectrically active material, such as a piezoelectric ceramic, crystal, plastic, and/or composite materials, as well as lithium niobate, lead titanate, barium titanate, and/or lead metaniobate. In addition to, or instead of, a piezoelectrically active material, transducer **404** can comprise any other materials configured for generating radiation and/or acous-

tical energy. Transducer **404** can also comprise one or more matching layers configured along with the transduction element such as coupled to the piezoelectrically active material. Acoustic matching layers and/or damping may be employed as necessary to achieve the desired electroacoustic response.

In accordance with an exemplary embodiment, the thickness of the transduction element of transducer **404** can be configured to be uniform. That is, transduction element **412** can be configured to have a thickness that is substantially the same throughout. In accordance with another exemplary embodiment, the thickness of transduction element **412** can also be configured to be variable. For example, transduction element(s) **412** of transducer **404** can be configured to have a first thickness selected to provide a center operating frequency of a lower range, for example from approximately 750 kHz to 5 MHz. Transduction element **404** can also be configured with a second thickness selected to provide a center operating frequency of a higher range, for example from approximately 5 MHz to 20 MHz or more. Transducer **404** can be configured as a single broadband transducer excited with at least two or more frequencies to provide an adequate output for generating a desired response. Transducer **404** can also be configured as two or more individual transducers, wherein each transducer comprises one or more transduction element. The thickness of the transduction elements can be configured to provide center-operating frequencies in a desired treatment range. For example, transducer **404** can comprise a first transducer configured with a first transduction element having a thickness corresponding to a center frequency range of approximately 750 kHz to 5 MHz, and a second transducer configured with a second transduction element having a thickness corresponding to a center frequency of approximately 5 MHz to 20 MHz or more.

Transducer **404** may be composed of one or more individual transducers in any combination of focused, planar, or unfocused single-element, multi-element, or array transducers, including 1-D, 2-D, and annular arrays; linear, curvilinear, sector, or spherical arrays; spherically, cylindrically, and/or electronically focused, defocused, and/or lensed sources.

In accordance with another exemplary embodiment, transducer probe **400** may be suitably configured to provide three-dimensional treatment. For example, to provide three-dimensional treatment of ROI **210**, with reference again to FIG. **4**, a three-dimensional system can comprise transducer probe **400** configured with an adaptive algorithm, such as, for example, one utilizing three-dimensional graphic software, contained in a control system, such as for example control system **300**. The adaptive algorithm is suitably configured to receive two-dimensional imaging, temperature monitoring and/or treatment information relating to ROI **210**, process the received information, and then provide corresponding three-dimensional imaging, temperature and/or treatment information.

In accordance with another aspect of the invention, transducer probe **400** may be configured to provide one, two or three-dimensional treatment applications for focusing acoustic energy to one or more regions of interest. For example, as discussed above, transducer probe **400** can be suitably diced to form a one-dimensional array, e.g., a transducer comprising a single array of sub-transduction elements.

For example, with reference to an exemplary embodiment depicted in FIG. **5**, exemplary transducer **500** can be configured as an acoustic array **502** to facilitate phase focusing.

That is, transducer **500** can be configured as an array of electronic apertures that may be operated by a variety of phases via variable electronic time delays. By the term “operated,” the electronic apertures of transducer **500** may be manipulated, driven, used, and/or configured to produce and/or deliver an energy beam corresponding to the phase variation caused by the electronic time delay. For example, these phase variations can be used to deliver defocused beams **508**, planar beams **504**, and/or focused beams **506**, each of which may be used in combination to achieve different physiological effects in ROI **210**. Transducer **500** may additionally comprise any software and/or other hardware for generating, producing and or driving a phased aperture array with one or more electronic time delays.

Transducer **500** can also be configured to provide focused treatment to one or more regions of interest using various frequencies. In order to provide focused treatment, transducer **500** can be configured with one or more variable depth devices to facilitate treatment. For example, transducer **500** may be configured with variable depth devices disclosed in commonly assigned U.S. patent application Ser. No. 10/944, 500, entitled “System and Method for Variable Depth Ultrasound”, filed on Sep. 16, 2004, published on Mar. 16, 2006, as U.S. Patent Application Publication No. 20060058664, and incorporated herein by reference. In some embodiments, transducer probe **104** or transducer probe **400** can comprise transducer **500**.

In addition, transducer **500** can also be configured to treat one or more additional ROI **210** through the enabling of sub-harmonics or pulse-echo imaging, as disclosed in commonly assigned U.S. patent application Ser. No. 10/944,499, entitled “Method and System for Ultrasound Treatment with a Multi-directional Transducer”, filed on Sep. 16, 2004, published on Mar. 16, 2006 as U.S. Patent Application Publication No. 20060058707, and incorporated herein by reference.

Moreover, any variety of mechanical lenses or variable focus lenses, e.g. liquid-filled lenses, may also be used to focus and/or defocus the sound field. For example, with reference to exemplary embodiments depicted in FIGS. **6A** and **6B**, transducer **600** may also be configured with an electronic focusing array **604** in combination with one or more transduction elements **606** to facilitate increased flexibility in treating ROI **210**. Array **604** may be configured in a manner similar to transducer **502**. That is, array **604** can be configured as an array of electronic apertures that may be operated by a variety of phases via variable electronic time delays, for example, $T_1, T_2 \dots T_j$. By the term “operated,” the electronic apertures of array **604** may be manipulated, driven, used, and/or configured to produce and/or deliver energy in a manner corresponding to the phase variation caused by the electronic time delay. For example, these phase variations can be used to deliver defocused beams, planar beams, and/or focused beams, each of which may be used in combination to achieve different physiological effects in ROI **210**.

Transduction elements **606** may be configured to be concave, convex, and/or planar. For example, in an exemplary embodiment depicted in FIG. **6A**, transduction elements **606** are configured to be concave in order to provide focused energy for treatment of ROI **210**. Additional embodiments of transducer **600** are disclosed in U.S. patent applications and U.S. patents that have been incorporated by reference herein.

In another exemplary embodiment, depicted in FIG. **6B**, transduction elements **606** can be configured to be substantially flat in order to provide substantially uniform energy to

ROI 210. While FIGS. 6A and 6B depict exemplary embodiments with transduction elements 604 configured as concave and substantially flat, respectively, transduction elements 604 can be configured to be concave, convex, and/or substantially flat. In addition, transduction elements 604 can be configured to be any combination of concave, convex, and/or substantially flat structures. For example, a first transduction element can be configured to be concave, while a second transduction element can be configured to be substantially flat. In some embodiments, transducer probe 104 or transducer probe 400 can comprise transducer 600.

To further illustrate the various structures for transducer 404, with reference to FIG. 7, ultrasound therapy transducer 700 can be configured for a single focus, an array of foci, a locus of foci, a line focus, and/or diffraction patterns. Transducer 700 can also comprise single elements, multiple elements, annular arrays, one-, two-, or three-dimensional arrays, broadband transducers, and/or combinations thereof, with or without lenses, acoustic components, and mechanical and/or electronic focusing. Transducers configured as spherically focused single elements 702, annular arrays 704, annular arrays with damped regions 706, line focused single elements 708, 1-D linear arrays 710, 1-D curvilinear arrays in concave or convex form, with or without elevation focusing, 2-D arrays, and 3-D spatial arrangements of transducers may be used to perform therapy and/or imaging and acoustic monitoring functions. For any transducer configuration, for example but not limited to including those employed in transducer probe 104 or transducer probe 400, focusing and/or defocusing may be in one plane or two planes via mechanical focus 720, convex lens 722, concave lens 724, compound or multiple lenses 726, planar form 728, or stepped form, such as illustrated in FIG. 10F. Any transducer or combination of transducers may be utilized for treatment. For example, an annular transducer may be used with an outer portion dedicated to therapy and the inner disk dedicated to broadband imaging wherein such imaging transducer and therapy transducer have different acoustic lenses and design, such as illustrated in FIGS. 10C-10F, as described below.

With reference to FIGS. 8A and 8B, transducer 404 can be configured as single-element arrays, wherein a single-element 802, e.g., a transduction element of various structures and materials, can be configured with a plurality of masks 804, such masks comprising ceramic, metal or any other material or structure for masking or altering energy distribution from element 802, creating an array of energy distributions 808. Masks 804 can be coupled directly to element 802 or separated by a standoff 806, such as any suitably solid or liquid material.

In accordance with another exemplary embodiment, transducer probe 104 or transducer probe 400 may be suitably diced in two dimensions to form a two-dimensional array. For example, with reference to FIG. 9, an exemplary two-dimensional array 900 can be suitably diced into a plurality of two-dimensional portions 902. Two-dimensional portions 902 can be suitably configured to focus on the treatment region at a certain depth, and thus provide respective slices 904, 907 of the treatment region. As a result, the two-dimensional array 900 can provide a two-dimensional slicing of image planes of a treatment region, thus providing two-dimensional treatment.

In accordance with another exemplary embodiment, transducer probe 400 may be suitably configured to provide three-dimensional treatment. For example, to provide three-dimensional treatment of ROI 210, with reference again to FIG. 3, a three-dimensional system can comprise transducer

probe 104 or transducer probe 400 configured with an adaptive algorithm, such as, for example, one utilizing three-dimensional graphic software, contained in a control system, such as for example control system 300. The adaptive algorithm is suitably configured to receive two-dimensional imaging, temperature and/or treatment information relating to ROI 210, process the received information, and then provide corresponding three-dimensional imaging, temperature and/or treatment information.

In accordance with an exemplary embodiment, with reference again to FIG. 9, an exemplary three-dimensional system can comprise a two-dimensional array 900 configured with an adaptive algorithm to suitably receive 904 slices from different image planes of the treatment region, process the received information, and then provide volumetric information 906, e.g., three-dimensional imaging, temperature and/or treatment information. Moreover, after processing the received information with the adaptive algorithm, the two-dimensional array 900 may suitably provide therapeutic heating to the volumetric region 906 as desired.

Alternatively, rather than utilizing an adaptive algorithm, such as three-dimensional software, to provide three-dimensional imaging and/or temperature information, an exemplary three-dimensional system can comprise a single transducer 404 configured within a probe arrangement to operate from various rotational and/or translational positions relative to a target region.

An exemplary transducer 404 can also be configured as an annular array to provide planar, focused and/or defocused acoustical energy. For example, with reference to FIGS. 10A and 10B, in accordance with an exemplary embodiment, an annular array 1000 can comprise a plurality of rings 1012, 1014, 1016 to N. Rings 1012, 1014, 1016 to N can be mechanically and electrically isolated into a set of individual elements, and can create planar, focused, or defocused waves. For example, such waves can be centered on-axis, such as by methods of adjusting corresponding transmit and/or receive delays, $T_1, T_2, T_3, \dots, T_N$. An electronic focus can be suitably moved along various depth positions, and can enable variable strength or beam tightness, while an electronic defocus can have varying amounts of defocusing. In accordance with an exemplary embodiment, a lens and/or convex or concave shaped annular array 1000 can also be provided to aid focusing or defocusing such that at any time differential delays can be reduced. Movement of annular array 1000 in one, two or three-dimensions, or along any path, such as through use of probes and/or any conventional robotic arm mechanisms, may be implemented to scan and/or treat a volume or any corresponding space within ROI 210.

Transducer 404 can also be configured in other annular or non-array configurations for imaging/therapy functions. For example, with reference to FIGS. 10C-10F, a transducer can comprise an imaging element 1012 configured with therapy element(s) 1014. Elements 1012 and 1014 can comprise a single-transduction element, e.g., a combined imaging/transducer element, or separate elements, can be electrically isolated 1022 within the same transduction element or between separate imaging and therapy elements, and/or can comprise standoff 1024 or other matching layers, or any combination thereof. For example, with particular reference to FIG. 10F, a transducer can comprise an imaging element 1012 having a surface 1028 configured for focusing, defocusing or planar energy distribution, with therapy elements 1014 including a stepped-configuration lens configured for focusing, defocusing, or planar energy distribution.

Various shaped treatment lesions can be produced using the various acoustic lenses and designs in FIGS. 10A-10F. For example, mushroom-shaped lesions may be produced from a spherically-focused source, and/or planar lesions from a flat source. That is, as the application of ablative ultrasound energy continues, this causes thermal expansion to generate a growing lesion. Concave planar sources and arrays can produce a "V-shaped" or ellipsoidal lesion. Electronic arrays, such as a linear array, can produce defocused, planar, or focused acoustic beams that may be employed to form a wide variety of additional lesion shapes at various depths. An array may be employed alone or in conjunction with one or more planar or focused transducers. Such transducers and arrays in combination produce a very wide range of acoustic fields and their associated benefits. A fixed focus and/or variable focus lens or lenses may be used to further increase treatment flexibility. A convex-shaped lens, with acoustic velocity less than that of superficial tissue, may be utilized, such as a liquid-filled lens, gel-filled or solid gel lens, rubber or composite lens, with adequate power handling capacity; or a concave-shaped, low profile, lens may be utilized and composed of any material or composite with velocity greater than that of tissue. While the structure of transducer source and configuration can facilitate a particular shaped lesion as suggested above, such structures are not limited to those particular shapes as the other spatial parameters, as well as the temporal parameters, can facilitate additional shapes within any transducer structure and source.

In accordance with an exemplary embodiment, with additional reference to FIG. 11, acoustic coupling and cooling 1140 can be provided to acoustically couple energy and imaging signals from transducer probe 1104 to and from ROI 210, to provide thermal control at the probe to ROI 210 interface 1110, and to remove potential waste heat from the transducer probe at region 1144. Temperature monitoring can be provided at the coupling interface via thermal sensor 1146 to provide a mechanism of temperature measurement 1148 and control via control system 1106 and thermal control system 1142. Thermal control may consist of passive cooling such as via heat sinks or natural conduction and convection or via active cooling such as with peltier thermoelectric coolers, refrigerants, or fluid-based systems comprised of pump, fluid reservoir, bubble detection, flow sensor, flow channels/tubing 1144 and thermal control 1142. In some embodiments, transducer probe 1104 can be equivalent to transducer probe 104 or transducer probe 400.

In accordance with another exemplary embodiment, with reference to FIG. 12, an exemplary treatment system 200 can be configured with and/or combined with various auxiliary systems to provide additional functions. For example, an exemplary treatment system 1200 for treating ROI 210 can comprise a control system 1206, a probe 1204, and a display 1208. In some embodiments, probe 1204 can be equivalent to transducer probe 104 or transducer probe 400 or transducer probe 1104. Treatment system 1200 further comprises an auxiliary imaging modality 1274 and/or auxiliary monitoring modality 1272 may be based upon at least one of photography and other visual optical methods, magnetic resonance imaging (MRI), computed tomography (CT), optical coherence tomography (OCT), electromagnetic, microwave, or radio frequency (RF) methods, positron emission tomography (PET), infrared, ultrasound, acoustic, or any other suitable method of visualization, localization, or monitoring of cellulite within ROI 210, including imaging/monitoring enhancements. Such imaging/monitoring enhancement for ultrasound imaging via probe 1204 and

control system 1206 could comprise M-mode, persistence, filtering, color, Doppler, and harmonic imaging among others; furthermore an ultrasound treatment system 1270, as a primary source of treatment, may be combined with a secondary source of treatment 1276, including radio frequency (RF), intense pulsed light (IPL), laser, infrared laser, microwave, or any other suitable energy source.

An ultrasound treatment system as described herein, as a primary source of treatment, may be combined with a secondary source of treatment configured to deliver secondary treatment energy. Secondary treatment energy includes, but is not limited to, radio frequency (RF) energy, microwave energy, infrared light, visible light, ultraviolet light, and any other suitable electromagnetic energy. Secondary treatment energy may be coherent (as in a laser), incoherent, scattered, pulsed, refracted, focused, defocused, and/or delivered in any other form suitable for achieving a bio-effect.

In an exemplary embodiment, ultrasound treatment is combined with blue light treatment. As used herein, "blue light" means electromagnetic energy having a wavelength from about 400 nanometers to about 440 nanometers. Blue light is applied to the skin. Blue light may be applied as a pretreatment before therapeutic ultrasound energy is applied. Blue light may also be applied concurrently with therapeutic ultrasound energy. Furthermore, blue light may be applied before, during, or after therapeutic ultrasound treatment, or during any combination thereof.

In accordance with an exemplary embodiment, blue light is applied to ROI 210 for a period between 5 seconds and 20 minutes. Blue light may be applied to ROI 210 for any suitable amount of time in order to achieve a desired bio-effect.

In another exemplary embodiment, ultrasound treatment is combined with red light treatment. As used herein, "red light" means electromagnetic energy having a wavelength from about 600 nanometers to about 1350 nanometers. Red light is applied to ROI 210. Red light may be applied as a pretreatment before therapeutic ultrasound energy is applied. Red light may also be applied concurrently with therapeutic ultrasound energy. Furthermore, red light may be applied before, during, or after therapeutic ultrasound treatment, or during any combination thereof.

In accordance with an exemplary embodiment, red light is applied to the skin for a period between 5 seconds and 20 minutes. Red light may be applied to the skin for any suitable amount of time in order to achieve a desired bio-effect.

In accordance with an exemplary embodiment, secondary treatment energy can be delivered by the probe which contains an ultrasound energy source. In other exemplary embodiments, secondary treatment energy is delivered by a source external to the probe. Secondary treatment energy may be generated by a light emitting diode (LED), a laser, an incandescent bulb, a fluorescent tube, an antenna, an intense pulsed light source, or any other suitable electromagnetic energy generation mechanism.

In one exemplary embodiment, energy is delivered in relatively small ablative areas in order to minimize and/or prevent scar tissue from forming. That is, each ablative area of treatment can range from approximately 100 microns to 55 mm in diameter. In another exemplary embodiment, ultrasound energy is used in a "lawnmower" type fashion to evenly ablate a treatment region to provide a substantially planar surface of lobuli. This "lawnmower"-type ablation in turn, helps to achieve a substantially smooth surface of the epidermis.

With reference to FIG. 13, another method of non-invasive treatment of cellulite is illustrated according to various other embodiments of the present invention. The cross-sectional diagram illustrates the layers of tissue below skin surface 1304 which is not to scale and is used for illustration purposes. Dermis layer 1302 includes skin surface 1304 and both the epidermis and dermis portions of the skin. Below the dermis layer 1302 is fat lobuli 1307. Fat lobuli 1307 causes protrusions in skin surface 1304, which gives skin surface 1304 a dimpled appearance 1311 or cellulite. Below fat lobuli 1307 is fascia layer 1315, subcutaneous fat layer 1317 and then muscle layer 1319.

In various aspects, probe 202 is coupled to skin surface 1304 and emits ultrasound energy to create conformal lesion 209 at specific depth 1305. Conformal lesion 209 ablates a portion of fat lobuli 1307. Probe movement 1303 along skin surface 1304 allows for ablation of a plurality of fat lobuli 1307 at specific depth 1305. This may be described as a lawnmower type ablation or a haircut of fat lobuli 1307. Probe movement 1303 leaves behind smoothed skin 1309. The treatment may need to be repeated in order to achieve a desired degree of smoothed skin 1309. This method may be combined with any other method steps described herein such as for example applying a physical treatment or applying a secondary energy source.

In accordance with an exemplary embodiment of the present invention, a method of non-invasive treatment of cellulite includes targeting ROI 210 below skin surface 1304, which contains fat lobuli 1307, and delivering ultrasound energy at specified depth 1305 below skin surface 1304. The method further includes moving a source of the energy along skin surface 1304 and ablating a portion of fat lobuli 1307 at specified depth 1305 below skin surface 1304.

Specified depth 1305 is generally in the range of about 1 mm to about 35 mm below skin surface 1304. The method can include applying a physical treatment as described herein. The method can smooth skin surface 1304 and may reduce the appearance of cellulite on skin surface 1304. The method can further include any of the additional method steps discussed herein.

With reference to FIG. 14, a method of non-invasive treatment of cellulite is illustrated according to another exemplary embodiment of the present invention. The cross-sectional diagram illustrates the layers of tissue below skin surface 1304 which is not to scale and is used for illustration purposes. Dermis layer 1302 includes skin surface 1304 and both the epidermis and dermis portions of the skin. Below dermis layer 1302 is fat lobuli 1307. Fat lobuli 1307 causes protrusions in skin surface 1304, which gives skin surface 1304 a dimpled appearance 1311 or cellulite. Below fat lobuli 1307 is fascia layer 1315, subcutaneous fat layer 1317 and then muscle layer 1319.

In the exemplary embodiment illustrated in FIG. 14A, probe 202 is coupled to skin surface 1304 and emits ultrasound energy to create conformal lesion 209 in the surface of fat lobuli 1307 to create opening 1321. A material that is housed in the punctured fat lobuli 1317 flows out of opening 1321. This material can be a fluid, a lipid, a lymphatic substance, fat, tissue, bodily materials, or any other material and mixtures thereof. The material can be any tissue, fluid, or the like that is typically housed in fat lobuli 1317. Moving to FIG. 14B, reduced fat lobuli 1325 has shriveled due to the loss of the material. The shrinking of reduced fat lobuli 1325 can cause smoothed skin 1309 above reduced fat lobuli 1325 which has been drained of the material, thereby reducing the appearance of cellulite on skin surface 1304.

In accordance with another exemplary embodiment, a method of non-invasive treatment of cellulite includes targeting ROI 210 below skin surface 1304, which contains fat lobuli 1307 and delivering ultrasound energy to ROI 210. The ultrasound energy generates conformal lesion 209 with the ultrasound energy on a surface of fat lobuli 1307. The lesion creates opening 1321 in the surface of fat lobuli 1307, which allows the draining of a fluid out of fat lobuli 1307 and through opening 1321.

The method can further include heating ROI 210 to a temperature in a range from about 43° C. to about 49° C., which can stimulate apoptosis of at least one fat cell in fat lobuli 1307. Still further the method can include applying a physical treatment to skin surface 1304 and such physical treatment can include mesotherapy, iontophoresis, pressotherapy, pneumatic massage, lymphatic drainage, electrolypophoresis, roller massage, low frequency ultrasound, vacuum suction, laser energy, and/or an application of RF energy. The physical treatment can be before, after, or concurrent with the delivery of the ultrasound energy. The method can include the use of a second energy, which can be used before, after, or concurrent with the delivery of the ultrasound energy. The method can reduce the appearance of cellulite on skin surface 1304.

With additional reference to FIG. 15, a block diagram illustrates an exemplary method for non-invasive treatment of cellulite according to various embodiments of the present invention. For example, method 1500 is a non-invasive treatment of cellulite. In step 1502, fat lobuli 1307 is targeted. Imaging the fat lobuli in a step 1503 may be useful in the targeting of fat lobuli 1307 but is optional or otherwise not required.

Targeting step 1502 is followed by energy delivery step 1504 which delivers ultrasound energy to form a conformal lesion 209 in the target which can be for example fat lobuli 1307. The ultrasound energy can be in the range from about 750 kHz to about 20 MHz and may be more useful in the range from about 2 MHz to about 10 MHz. The power of the ultrasound energy may be in a range from about 1 W to about 50 W and may be more useful in the range from about 2 W to about 20 W. The duration of the ultrasound energy may be in the range from about 10 milliseconds to about 20 minutes, or even more if desired. Energy delivery step 1504 may include applying secondary energy step 1505, which is optional. Applying a secondary energy step 1505 may be useful in heating the tissue around the target to an elevated temperature prior to or during delivery of ultrasound energy to the targeted region, and can comprise a variety of energy sources including those discussed previously herein.

Energy delivery step 1504 is followed by creating an opening in the target step 1506, which provides an opening 1321. In this step 1506, conformal lesion 209 creates opening 1321 in the target. Upon creating an opening in the target, step 1506 is followed by a release of contents step 1508, in which at least a portion of the contents of fat lobuli 1307 are released through opening 1321, e.g., by draining. An application of secondary energy step 1505 may be applied after the creation of opening 1321 but is optional. Such application of secondary energy step 1505 may be useful in smoothing skin surface 1304 and/or in facilitating movement of at least a portion of the contents of fat lobuli 1307 to facilitate their release. The contents of fat lobuli 1307 can be a fluid, a lipid, a lymphatic substance, fat, tissue, bodily materials, or any other material and mixtures thereof. An application of physical treatment step 1507, such as, for example, by applying physical pressure or force to facilitate movement, may be useful in facilitating the releas-

ing of at least a portion of the contents of fat lobuli 1307 through opening 1321, but this step 1507 is optional. An optional imaging step 1509 can be added for reviewing if the treatment was successful. If the treatment complete decision 1511 is yes, then the result is the final step 1510 wherein the skin is smoothed. If the treatment complete decision 1511 is no, then move to step 1504 for further treatment of the target until the treatment is successful within the treatment area, resulting in the smoothing of skin step 1510 which reduces the appearance of cellulite on skin surface 1304.

In accordance with another exemplary embodiment, a method of non-invasive treatment of cellulite includes identifying fat lobuli 1307 and creating a sharp focal of ultrasound energy onto fat lobuli 1307. The focal of energy pierces fat lobuli 1307 to create opening 1321, which then allows the flowing of a material out of fat lobuli 1307 through opening 1321. The method can further include any of the additional method steps discussed herein.

Now referring to FIG. 16, a method of non-invasive treatment for a reduction of fat is illustrated according to another exemplary embodiment of the present invention. In various embodiments, this method can be used as a non-invasive treatment of cellulite. The cross-sectional diagram illustrates the layers of tissue below skin surface 1304 which is not to scale and is used for illustration purposes. Dermis layer 1302 includes skin surface 1304 and both the epidermis and dermis portions of the skin. Below dermis layer 1302 is fat lobuli 1307. Fat lobuli 1307 causes protrusions in skin surface 1304, which gives skin surface 1304 a dimpled appearance 1311 or cellulite. Below fat lobuli 1307 is fascia layer 1315, subcutaneous fat layer 1317 and then muscle layer 1319.

In an exemplary embodiment, as illustrated in FIG. 16A, probe 202 is coupled to skin surface 1304 and emits ultrasound energy into adipose target area 1331. Adipose target area 1331 can include a portion of fat lobuli 1307. Adipose target area 1331 can include ROI 210. Fat lobuli 1307 can contain a plurality of adipose cells and a portion of the plurality of adipose cells can be located in adipose target area 1331. Adipose target area 1331 can include a plurality of other adipose cells 1329 that may be amongst fat lobuli 1307.

Probe 202 is targeted to deliver energy in adipose target area 1331. Adipose target area 1331 can be from about 1 mm to about 100 mm or greater below skin surface 1304. Height 1333 of adipose target area 1331 can be from about 1 mm to about 10 mm or greater. Probe 202 delivers energy to create at least one conformal lesion 209 in adipose target area 1331. Delivered energy raises a temperature of at least a portion of adipose cells in fat lobuli 1307 and/or other adipose cells 1329 located in adipose target area 1331 to a range from about 43° C. to about 49° C., which stimulates apoptosis of fat cells, which can include at least a portion of other adipose cells in fat lobuli 1307 and/or other adipose cells 1329.

As illustrated in FIG. 16B, over a period of time, the portion of the plurality of adipose cells fat lobuli 1307 that were located in adipose target zone 1331 begin cell apoptosis. As these adipose cells die, fat lobuli 1307 shrinks. This cell apoptosis of the adipose cells reduces the amount of fat in an area on a patient. The effect of the reduction in size of fat lobuli 1307 by the adipose cell apoptosis can create smoothed skin 1309. In addition, other adipose cells 1329 that were located in adipose target area 1331 can begin cell apoptosis. As these other adipose cells 1329 die, skin surface 1304 can relax, which can contribute to creating smoothed

skin 1309. Probe 202 can be moved along skin surface 1304 to enlarge the treatment of adipose target area 1331 of a patient's body.

An exemplary method, such as that illustrated by FIG. 16, can include applying a physical treatment to skin surface 1304, and such physical treatment can include mesotherapy, iontophoresis, pressotherapy, pneumatic massage, lymphatic drainage, electrolipophoresis, roller massage, low frequency ultrasound, vacuum suction, laser energy, and application of RF energy. The physical treatment can be before, after, or concurrent with the delivery of the energy. The method can include the use of a second energy, which can be used before, after, or concurrent with the delivery of the energy.

With reference to FIG. 17, a block diagram illustrates a method 1600 of fat reduction according to an exemplary embodiment. For example, the method 1600 begins with step 1602 which is the targeting of a group of fat cells in adipose target area 1331. This targeting step 1602 may include the movement of probe 202 to include an enlarged target area. In targeting step 1602 a depth below skin surface 1304 that is appropriate for adipose target area 1331 is determined. Generally, a depth of greater than 1 mm but less than 100 mm is appropriate and this can vary from patient to patient depending on location on the body and level of patient's body fat.

Targeting step 1602 is followed by energy delivery step 1603 which is the delivering of ultrasound energy to the target fat cells. The ultrasound energy can be in the range from about 750 kHz to about 20 MHz and may be more useful in the range from about 2 MHz to about 10 MHz. The power of the ultrasound energy may be in a range from about 1 W to about 50 W and may be more useful in the range from about 2 W to about 20 W. The duration of the ultrasound energy may be in the range from about 10 milliseconds to about 20 minutes, or more if desired.

Energy delivery step 1603 is followed by raising temperature step 1604, which is the raising of the fat cell temperature from about 43.5° C. to about 49° C. Different combinations of parameters outlined in energy delivery step 1603 can be useful to raise the fat cell temperature to the desired range in step 1604. Raising temperature step 1604 creates or facilitates the stimulating apoptosis step 1605 which is the stimulating cell apoptosis of the fat cells in adipose target area 1331. If the fat cells are held in the desired temperature range for a sufficient amount of time, cell apoptosis will occur. Stimulating apoptosis step 1605 is followed by step 1606 which is the allowing of the targeted fat cells and/or targeted portions thereof to die. Upon allowing target portions to die in step 1606 results, a reduction of the total number of fat cells in adipose target area 1331 is achieved 1607. This reduction of the total number of fat cells can result in lowering the circumference of a patient's body, for example the circumference of thighs, buttocks, hips, waist, and the like. In addition, this reduction of adipose target area 1331 can reduce an appearance of cellulite on skin surface 1304. Alternatively, or simultaneously, method 1600 can target fat cells in the subcutaneous fat layers to provide similar results.

Now with reference to FIGS. 18A and 18B, a method of non-invasive treatment for a reduction of fat is illustrated according to various exemplary embodiments of the present invention. In various embodiments, this method can be used as a non-invasive treatment of subcutaneous fat layer 1317. The cross-sectional diagram illustrates the layers of tissue below skin surface 1304 which is not to scale and is used for illustration purposes. The dermis layer 1302 includes skin

surface **1304** and both the epidermis and dermis portions of the skin. Below dermis layer **1302** is fat lobuli **1307**. Fat lobuli **1307** causes protrusions in skin surface **1304**, which gives skin surface **1304** a dimpled appearance **1311** or cellulite. Below fat lobuli **1307** is fascia layer **1315**, subcutaneous fat layer **1317** and then muscle layer **1319**. Subcutaneous fat layer **1317** can have a selected depth **1337**.

In an exemplary embodiment as illustrated in FIG. **18A**, probe **202** is coupled to skin surface **1304** and emits ultrasound energy into adipose target area **1331**. Adipose target area **1331** can include a portion of subcutaneous fat layer **1317**. Subcutaneous fat layer **1317** can contain a plurality of adipose cells and a portion of the plurality of adipose cells can be located in adipose target area **1331**.

Probe **202** is targeted to deliver energy in adipose target area **1331**. Adipose target area **1331** can be from about 1 mm to about 100 mm or greater below the surface of the skin **1304**. Height **1333** of adipose target area **1331** can be from about 1 mm to about 10 mm or greater. Probe **202** delivers energy to create at least one conformal lesion **209** which is located in adipose target area **1331**. Delivered energy raises a temperature of at least a portion of the adipose cells located in adipose target area **1331** in to a range from about 43° C. to about 49° C., which stimulates apoptosis of the fat cells, which can include at least a portion of adipose cells in fat lobuli **1307** and/or other adipose cells **1399**.

Over a period of time, the portion of the plurality of adipose cells in subcutaneous fat layer **1317** that were located in adipose target area **1331** begin cell apoptosis. As these adipose cells die, subcutaneous fat layer **1317** shrinks. This cell apoptosis of the adipose cells reduces the amount of fat in an area on a patient. As illustrated in FIG. **18B**, the effect of the adipose cell apoptosis in subcutaneous fat layer **1317** can create smoothed skin **1309**.

In addition, the effect of the adipose cell apoptosis in subcutaneous fat layer **1317** can create a reduction **1335** in the total volume of tissue in the treatment area. In accordance with the method, probe **202** can be moved along skin surface **1304** to enlarge the treatment of adipose target area **1331** of a patient's body. For example, this reduction **1335** can cause a decrease in the circumference of a patient's thighs, buttocks, hips, waist, and the like. As the adipose cell apoptosis in subcutaneous fat layer **1317** continues, skin surface **1304** can relax and can contribute to creating smoothed skin **1309**. Subcutaneous fat layer **1317** can have a reduced depth **1339** after cell apoptosis. Reduced cell depth **1339** generally results from thickness of depth **1337** less the thickness **1333** of adipose target area **1331**, i.e., the portion shrunk from cell apoptosis.

Various exemplary methods as illustrated in FIG. **18** provide a method of non-invasively stimulating apoptosis of a fat cell located in subcutaneous fat layer **1317**. The method includes targeting at least one fat cell in subcutaneous fat layer **1317** below skin surface **1304** and delivering energy to the fat cell. The delivered energy raises a temperature of the fat cell into a range from about 43° C. to about 49° C., which stimulates apoptosis of the fat cell.

The method can further include imaging of a fat cell or fat lobuli **1307**. Still further, the method can include generating conformal lesion **209** into at least one fat cell, which can create opening **1321** in a fat cell or fat lobuli **1307** and allow the moving of a material out of a fat cell or fat lobuli **1307** and through opening **1321**. This material can be a fluid, a lipid, a lyphomatic substance, fat, tissue, bodily materials, or any other material and mixtures thereof. The ultrasound energy can be in the range from about 750 kHz to about 20 MHz and may be more useful in the range from about 2 MHz

to about 10 MHz. The power of the ultrasound energy may be in a range from about 1 W to about 50 W and may be more useful in the range from about 2 W to about 20 W. The duration of the ultrasound energy may be in the range from about 10 milliseconds to about 20 minutes. Still further, the method can include applying a physical treatment to skin surface **1304** and such physical treatment can include mesotherapy, Iontophoresis, pressotherapy, pneumatic massage, lymphatic drainage, electrolipophoresis, roller massage, low frequency ultrasound, vacuum suction, laser energy, and application of RF energy. The physical treatment can be before, after, or concurrent with the delivery of the energy. The method can include the use of a second energy, which can be used before, after, or concurrent with the delivery of the energy. The method can reduce the number of fat cells in subcutaneous fat layer **1317**.

In addition, various other exemplary embodiments of the present invention can include a method that combines fat reduction and cellulite reduction. The method includes targeting ROI **210** below skin surface **1304**, which contains fat lobuli **1307** and delivering ultrasound energy to ROI **210**. The ultrasound energy generates conformal lesion **209** with said ultrasound energy on a surface of fat lobuli **1307**. Conformal lesion **209** creates opening **1321** in the surface of fat lobuli **1307**, which allows the draining of a fluid out of fat lobuli **1307** and through opening **1321**. Additionally, the method can include targeting at least one fat cell in subcutaneous fat layer **1321** below skin surface **1304** and delivering a second energy to the fat cell. The delivered second energy raises a temperature of the fat cell into a range from about 43° C. to about 49° C., which stimulates apoptosis of the fat cell.

The method can further include a physical treatment as described herein, as well as the use of a secondary energy source. The method can both reduce the number of fat cells in subcutaneous fat layer **1317** and reduce the appearance of cellulite on skin surface **1304**. The method can be effective in the physically breaking fat cell clusters and stretching fibrous bonds of cellulite.

In accordance with another exemplary embodiment of the present invention, a method of non-invasive treatment of cellulite includes identifying fat lobuli **1307** and creating a sharp focal of ultrasound energy onto fat lobuli **1307**. The focal of energy pierces fat lobuli **1307** to create opening **1321**, which then allows the flowing of a material out of fat lobuli **1307** through opening **1321**. The method can further include any of the additional method steps discussed herein.

In various embodiments, the energy is delivered at a treatment depth from about 0 mm to about 50 mm or about 1 mm to about 35 mm. The ultrasound energy can be in the range from about 750 kHz to about 20 MHz and may be more useful in the range from about 2 MHz to about 10 MHz. The power of the ultrasound energy may be in a range from about 1 W to about 50 W and may be more useful in the range from about 2 W to about 20 W. The duration of the ultrasound energy may be in the range from about 10 milliseconds to about 20 minutes.

Once the treatment protocol, for any of the methods of treatment discussed herein or variations thereof, has been implemented, ROI **210** may have one or more reactions to the treatment. For example, in some embodiments, the tissue responds by enhancement of lymphatic drainage, evacuation of fat decay products, creation of a thermal injury and/or coagulation of proximal protrusions of fat lobuli **1307**.

In an exemplary embodiment, energy such as ultrasound energy is emitted from a treatment system at multiple depths to target numerous areas within a specific ROI **210**. Multiple

layers of tissue within ROI **210** are treated from the surface down to the deepest point of ultrasound energy penetration and no intervening layers of tissue are spared in one embodiment of the present invention. In addition to ultrasound energy, other energy forms such as laser energy, radio frequency energy, and other energies can be used and fall within the scope of the present invention. Further, blue light at a wavelength of approximately 400 to 450 nm can be used to pre-treat ROI **210** before the application of ultrasound energy or blue light of this wavelength can be used with ultrasound to increase the efficacy of treatment. In another embodiment, visible light in the range of 600 to 1350 nm can be used with the ultrasound during treatment.

Upon treatment, the steps outlined herein can be repeated one or more additional times to provide for optimal treatment results. Different ablation sizes and shapes of conformal lesion **209** may affect the recovery time and time between treatments. For example, in general, the larger the surface area of conformal lesion **209**, the faster the recovery. The series of treatments can also enable the user to tailor additional treatments in response to a patient's responses to the ultrasound treatment.

The methods of treatment described herein can employ various shaped conformal lesions **209** and can be produced using the various acoustic lenses and designs described herein. For example, mushroom shaped lesions may be produced from a spherically-focused source, and/or planar lesions from a flat source. That is, as the application of ablative ultrasound energy continues, this causes thermal expansion to generate a growing lesion. Concave planar sources and arrays can produce a "V-shaped" or ellipsoidal lesion. Electronic arrays, such as a linear array, can produce defocused, planar, or focused acoustic beams that may be employed to form a wide variety of additional lesion shapes at various depths. Other lesion shapes that may be useful with the treatment methods described herein include the lesion shapes and patterns described in the U.S. patents and U.S. patent application that are incorporated by reference herein.

The citation of references herein does not constitute admission that those references are prior art or have relevance to the patentability of the invention disclosed herein. All references cited in the Description section of the specification are hereby incorporated by reference in their entirety for all purposes. In the event that one or more of the incorporated references differs from or contradicts this application, including, but not limited to, defined terms, term usage, described techniques, or the like, this application controls.

The present invention has been described above with reference to various exemplary embodiments. However, those skilled in the art will recognize that changes and modifications may be made to the exemplary embodiments without departing from the scope of the present invention. For example, the various operational steps, as well as the components for carrying out the operational steps, may be implemented in alternate ways depending upon the particular application or in consideration of any number of cost functions associated with the operation of the system, e.g., various steps may be deleted, modified, or combined with other steps. These and other changes or modifications are intended to be included within the scope of the present invention, as set forth in the following claims.

What is claimed is:

1. An ultrasound treatment system for treatment of fat, the system comprising:

an ultrasound probe comprising a motion mechanism and a therapy component,

wherein the therapy component comprises of:

an ultrasound therapy element that delivers ultrasound energy at a frequency of between 2 MHz to 10 MHz, wherein the ultrasound therapy element is a spherically focused element or a cylindrically focused element,

wherein the ultrasound therapy element is configured for delivery of energy at a temperature sufficient to coagulate at least a portion of a plurality of fat lobuli at a depth under a skin surface,

wherein the ultrasound therapy element is connected to the motion mechanism, and

a control system comprising a processor and power supply;

wherein the ultrasound probe is configured for acoustic coupling to the skin surface,

wherein the ultrasound therapy element is in communication with the control system,

wherein the motion mechanism is in communication with the control system,

wherein the motion mechanism moves the ultrasound therapy element to form a plurality of thermal foci at the depth for coagulating the at least a portion of the plurality of fat lobuli.

2. The system of claim 1, further comprising:

a user control switch to activate the ultrasound therapy element, wherein the ultrasound energy increases a speed at which fat metabolizes according to Arrhenius Law: $Y=A \cdot e^{-B/T}$, where Y is a yield of metabolic reaction, A and B are constants, and T is a temperature in degrees Kelvin.

3. The system of claim 1, further comprising a monitoring system,

wherein the monitoring system is configured to monitor a treatment parameter, wherein the treatment parameter measured comprises a temperature of a tissue below the skin surface, and

wherein the ultrasound probe further comprises a temperature monitoring sensor.

4. The system of claim 1,

wherein the motion mechanism comprises an encoder, wherein the motion mechanism is configured to form a plurality of thermal lesions along a line at the depth in a region of interest by moving the ultrasound therapy element.

5. The system of claim 1, further comprising an acoustic coupler between the ultrasound probe and the skin surface, wherein the motion mechanism comprises an encoder, and wherein the motion mechanism is configured for any one of the group consisting of linear, rotational, and variable movement of the ultrasound therapy element within the ultrasound probe.

6. The system of claim 1,

wherein the motion mechanism comprises an encoder for monitoring a position of the ultrasound therapy element on the motion mechanism inside the ultrasound probe, wherein the ultrasound therapy element is configured to deliver the energy at the depth below the skin surface.

7. The system of claim 1, further comprising a monitoring system,

wherein the monitoring system is configured to monitor a treatment parameter, wherein the treatment parameter comprises a temperature of a tissue below the skin surface,

wherein the ultrasound probe further comprises a temperature monitoring sensor,

27

wherein the therapy element is configured to increase the temperature of the tissue to a range of 43 to 49 degrees Celsius,

wherein the ultrasound energy is delivered with a treatment power of between 1 W and 50 W.

8. The system of claim 1, further comprising an ultrasound imaging element and a display.

9. An ultrasound treatment system for treatment of fat, the system comprising:

an ultrasound probe comprising a therapy component,

wherein the therapy component comprises:

a cylindrically focused ultrasound therapy element, wherein the cylindrically focused ultrasound therapy element delivers ultrasound energy at a frequency of between 750 kHz to 20 MHz,

wherein the cylindrically focused ultrasound therapy element is configured for delivery of ultrasound energy at a temperature sufficient to coagulate one or more fat lobuli at a depth under a skin surface, and a motion mechanism;

wherein a portion of the ultrasound probe is configured for acoustic coupling to the skin surface; and

wherein the cylindrically focused ultrasound therapy element is connected to the motion mechanism,

wherein the motion mechanism moves the cylindrically focused ultrasound therapy element to coagulate the fat lobuli.

10. The system of claim 9,

wherein the ultrasound probe further comprises an ultrasound imaging element,

wherein the ultrasound imaging element is configured for imaging a region of interest under the skin surface, wherein the region of interest comprises the fat lobuli.

11. The system of claim 9,

wherein the cylindrically focused ultrasound therapy element delivers ultrasound energy at a frequency of between 2 MHz to 10 MHz, and

wherein the ultrasound energy increases a speed at which fat metabolizes according to Arrhenius Law: $Y=A \cdot e^{-B/T}$, where Y is a yield of metabolic reaction, A and B are constants, and T is a temperature in degrees Kelvin.

12. The system of claim 9,

wherein the cylindrically focused ultrasound therapy element is configured to deliver the ultrasound energy up to 5.5 cm below the skin surface,

wherein the ultrasound energy is delivered with a treatment power of between 1 W and 50 W.

13. An ultrasound treatment system for treatment of fat, the system comprising:

an ultrasound probe comprising a motion mechanism and a therapy component,

28

wherein the therapy component comprises an ultrasound therapy element,

wherein a portion of the ultrasound probe is configured for acoustic coupling to a skin surface; and

a control system;

wherein the ultrasound therapy element is configured for delivery of ultrasound energy to a region of interest under the skin surface, wherein the ultrasound therapy element is configured to coagulate at least a portion of a plurality of fat lobuli at a depth under the skin surface, wherein the ultrasound therapy element is connected to the motion mechanism,

wherein the motion mechanism moves the ultrasound therapy element to form a plurality of thermal lesions at the portion of the plurality of fat lobuli at the depth for reducing an appearance of fat.

14. The system of claim 13,

wherein the therapy element delivers the ultrasound energy at a frequency of between 2 MHz to 10 MHz,

wherein the ultrasound therapy element is configured to deliver the ultrasound energy at the depth below the skin surface.

15. The system of claim 13, wherein the ultrasound energy is configured for heating the plurality of fat lobuli to a temperature in a range of 43 to 49 degrees Celsius.

16. The system of claim 13, further comprising a monitoring system,

wherein the monitoring system is configured to monitor a treatment parameter,

wherein the treatment parameter measured comprises a temperature of the tissue below the skin surface,

wherein the ultrasound probe further comprises a temperature monitoring sensor,

wherein the control system comprises a spatial control and a temporal control, the spatial control and the temporal control controlling the delivery of energy to heat the plurality of fat lobuli at the depth under the skin surface.

17. The system of claim 13, further comprising a user control switch to activate the ultrasound therapy element and wherein the ultrasound energy increases a speed at which fat metabolizes according to Arrhenius Law: $Y=A \cdot e^{-B/T}$, where Y is a yield of metabolic reaction, A and B are constants, and T is a temperature in degrees Kelvin.

18. The system of claim 13, wherein the control system comprises: an input device and a power supply.

19. The system of claim 13, wherein the therapy element is a spherically focused single element.

20. The system of claim 13, wherein the therapy element is a cylindrically focused single element.

* * * * *

专利名称(译)	基于能量的脂肪减少		
公开(公告)号	US9713731	公开(公告)日	2017-07-25
申请号	US15/380267	申请日	2016-12-15
申请(专利权)人(译)	引导治疗系统公司		
当前申请(专利权)人(译)	引导治疗系统公司		
[标]发明人	SLAYTON MICHAEL H BARTHE PETER G		
发明人	SLAYTON, MICHAEL H. BARTHE, PETER G.		
IPC分类号	A61N7/00 G01S15/89 G01S7/52 B06B1/06 A61B5/00 A61B8/08 A61B90/00 A61N7/02		
CPC分类号	A61N7/00 A61B5/4869 A61B8/0858 B06B1/0607 G01S7/5208 G01S15/899 A61B2090/378 A61N2007/0008 A61N2007/0052 A61N2007/027 A61B8/14 A61B8/429 A61B8/4455 A61B8/4483 A61B8/483 A61N7/02 B06B1/0622 G01S15/8906 G01S15/8993 H05K999/99		
优先权	14/550772 2016-03-15 US 14/192520 2014-12-30 US 12/646609 2014-03-04 US 11/163154 2012-03-13 US 60/616753 2004-10-06 US 61/140725 2008-12-24 US		
其他公开文献	US20170095680A1		
外部链接	Espacenet USPTO		

摘要(译)

用于非侵入性脂肪减少的方法可以包括将皮肤表面下方的感兴趣区域靶向，其包含脂肪并将超声能量传递到感兴趣的区域。超声能量在脂肪细胞上产生具有所述超声能量的热损伤。病变可以在脂肪细胞的表面中形成开口，这允许流体从脂肪细胞排出并通过开口。另外，通过向脂肪细胞施加超声能量以将温度升高到43度和49度之间，可以实现细胞凋亡，从而导致脂肪减少。

